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ABSTRACT
REGULATION OF THE HCMV UL98 PROMOTER BY 
COOPERATION OF THE CYCLIC AMP RESPONSE ELEMENT 
AND GAMMA INTERFERON RESPONSE ELEMENT
Tabmitha Patricia Young Jervey 
Eastern Virginia Medical School and Old Dominion University, 2001 
Director: Dr. Richard M. Stenberg
The HCMV UL98 early alkaline exonuclease gene promoter was examined to 
determine the DNA sequences as well as viral and/or cellular proteins functional in the 
regulation of this early gene. To assess promoter activation, UL98 promoter sequences 
were first cloned upstream of the chloramphenicol acetyltransferase (CAT) reporter gene 
and cotransfected with expression plasmids which express the HCMV major immediate 
early (IE) proteins IE72 and IE86. To more specifically determine the importance of 
individual cis-acting elements in UL98 promoter activation, the promoter region 
underwent mutagenesis to delete or alter sequences. The variant promoters were again 
cloned into a reporter-C AT construct and analyzed in transient transfection assays to 
assess changes in promoter activity in response to viral or virally induced proteins.
Analysis of promoter activation indicated that the UL98 promoter required the 
presence of the IE72 and EE86 immediate early (IE) proteins. In comparison to a 
prototypical early promoter which regulates the polymerase (pol) gene, UL98 promoter 
activation levels were equal to or even greater than that of pol in response to the IE 
transactivators. In the presence of all viral proteins, activation of the UL98 promoter 
continually increased when analyzed at 24,48, and 72 hours.
Deletion analysis showed that a 13 bp sequence located between -64 and -51 is
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required for UL98 promoter activation by IE proteins. Site-directed mutations generated 
in two cellular transcription factor binding sites resulted in a drastic reduction in 
promoter activation. A mutation in the cyclic AMP response element (CRE) (-82 to -75) 
resulted in a 70% loss of promoter activation. The UL98 promoter was also poorly 
activated in the presence of a mutation generated in the gamma interferon response 
element (yIRE) (-37 to -30), a transcription factor binding site downstream o f-5 1. 
Binding and competition experiments via gel mobility shift assays provided conclusive 
evidence that the CREB protein binds the CRE site in the UL98 promoter.
These data indicate that the UL98 early promoter is regulated primarily by the 
CRE and gamma IRE sequences. UL98 promoter activation therefore relies upon the 
presence of a combination of elements in their defined flanking positions.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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ICHAPTER I 
INTRODUCTION 
Cytomegaloviruses: classification and general characteristics
Human cytomegalovirus (HCMV) is a large animal DNA virus categorized under 
the family Herpesviridae, subfamily beiaherpesvirinae, and the genera 
cytomegaloviruses. Eight human herpesviruses (HHV) have been identified to date. 
HCMV (HHV5) is the fifth of the herpesviruses which includes herpes simplex type 1 
(HSV 1), herpes simplex type 2 (HSV 2), varicella zoster virus (VZV), Epstein-Barr virus 
(EBV), human herpesvirus 6 (HHV6), human herpesvirus 7 (HHV7), and Kaposi’s- 
sarcoma associated human herpesvirus 8 (HHV 8) (153). As a betaherpesvirus member, 
cytomegaloviruses are characterized by the ability to persist in a restricted host range. 
Previously known as salivary gland viruses, the virus-induced cytopathic effects called 
cytomegalia and the viral role in congenitally acquired cytomegalic inclusion disease 
(CID) prompted the new name cytomegalovirus (reviewed in reference 125).
In addition to the unique characteristic of salivary gland tropism, HCMV also 
grows slowly in culture and is species specific. It is highly distributed in nature with 
greater than 50% of the U.S. population outside urban centers acquiring HCMV in early 
childhood. Greater than 90% of the U.S. population in urban centers are infected with 
HCMV. HCMV establishes a persistent infection which can lie latent in the host for life 
causing no harm. However, the pathogenic effects of HCMV have been more apparent in 
recent years due to its association with patients having suppressed immune systems as a
The model for this thesis is Journal of Virology.
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2result of acquired immune deficiency syndrome (AIDS) as well as transplant patient 
recipients under post immunosuppressive therapies.
Human cytomegalovirus: Discovery and isolation.
Cytomegalovirus infection characteristically results in enlarged cells with 
intranuclear inclusions very similar to those produced by other herpesviruses (i.e., HSV, 
VZV) (12). In the early 1900s, the cellular changes observed in patient tissues were 
thought to have been a consequence of protozoan or syphilitic infection. Jesionek and 
Kiolemenoglou observed the presence of protozoan-like cells in several organs of a leutic 
fetus (IS, 70). Ribbert reported observing similar cells on two separate occasions (15,
70). Infant organs such as the submaxillary glands were noted postmortem as having 
similar cellular changes (70). It was from these observations that the term “cytomegalic 
inclusion disease” (CID) was named. In 1921, Lipschutz compared the intranuclear 
inclusions he observed to herpetic lesions thereby proposing that a virus may be the 
causative agent for CID (15, 70). Cole and Kuttner provided the initial experimental 
evidence for virus induced CID (30). Using a guinea pig model, they showed that filtered 
homogenates of salivary glands with intranuclear inclusions were indeed infectious to 
animals. The animals had no prior evidence of CID. A causative agent was proposed 
soon after salivary gland tissues from infected animals were compared to the infected 
salivary glands from human tissue. The virus was named the “salivary gland virus”.
In the 1950’s, the virus was isolated by three independent laboratories. Smith 
and Weller, in 1956 and 1957, respectively, each isolated the virus from infants with 
CID (175, 220). The term “cytomegalovirus” was first used by Weller et al. to reflect the
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
3cytopathology produced by the virus (219). Rowe isolated the laboratory adapted strain 
of the virus now called AD169 (155). The adenoidal tissue was taken from a child who 
had undergone tonsil and adenoidectomies. Instead of isolating adenovirus, the AD 169 
strain of the virus was fortuitously isolated. Cytomegalovirus isolated from humans 
finally became known as human cytomegalovirus (HCMV). Serology indicated that 
HCMV infection was a common, usually subclinical infection that occurs worldwide. In 
infants, the elderly, and especially the immunocompromised, the infection becomes more 
severe. CMV classification as a member of the Herpesviridae family was decided based 
on viral morphology and its DNA composition.
Virion Structure
The structure and composition of the CMV virion resembles that of other virions 
in the herpesvirus family. The virion of cytomegalovirus is the most extensively 
characterized of the beta herpesvirus group (50). Pleomorphic in shape, mature virions 
usually range in size from 150 to 200 nm. The components include a large double- 
stranded DNA, a central core, an icosahedral capsid, a tegument, and the trilaminate 
envelope. The genome is linear and is located within the central core of the particle. The 
capsid, composed of 162 capsomeres, surrounds the core with a diameter of 
approximately 110 nanometers (nm). At least four capsid proteins are present in virions. 
90% of the capsid protein consists of the major capsid protein (MCP, UL86) (153.8 kD) 
(51), the minor capsid protein (mCP, UL85) of 34.6 kD, the minor capsid binding protein 
(mC-BP, UL46) of 33 kD, and the smallest capsid protein (scp, UL48/49) of 8.5 kD. The 
tegument, which lies between the capsid and the envelope, has not yet been characterized
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4functionally. The tegument contains twenty proteins on its surface and makes up 
approximately 40 % of the CMV virion protein mass. Five predominant proteins of the 
tegument include UL48 (250 kD), UL47 or hmw-BP (110 kD), UL32 or ppl50 (113 kD), 
UL82 or pp71 (62 kD), and the UL83 or pp65 (63 kD). The latter three proteins are 
phosphorylated in vivo and in vitro (74, 112, 151) and only the pp71 phosphoprotein has 
been functionally characterized; a transcriptional transactivator of the HCMV major 
immediate early promoter (124). Lastly, the virion envelope, which surrounds the 
tegument, is derived from the infected cell plasma membrane and contains most of the 
virion glycoproteins. Of the eight identified glycoproteins in CMV, only four have been 
confirmed as HSV homologs: gB, gH, gL, and gM (16). While other glycoproteins have 
been identified, their function has not yet been elucidated. gB studies suggest that this 
glycoprotein participates in the attachment and fusion of the virion to the host cell 
membrane by binding heparin, a widely expressed cell surface protein (reviewed in 153). 
gL has been shown to associate with the gH glycoprotein and function in the fusion 
process. gM is thought to participate in the heparin-binding activity due to its presence in 
the gCn complex (83).
Organization of the viral genome
Characterization of the herpesvirus DNA to date is based on size, conformation, 
base composition, and sequence arrangement. Herpesvirus DNA was found to be linear, 
double-stranded, and the molecular weight ranges from 120 to 230 kilobase pairs (kbp) 
(153). Base composition of the different herpesvirus DNAs range from 31 to 75 G+C 
mole % (153). The sequence arrangement of the DNA’s among the herpesviruses is a
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5most interesting feature. Reiterations of terminal repeats greater than 100 bp occur both 
within the genome and/or at the termini. This characteristic allows for the classification 
of the genome varieties into six different groups from A to F depending on how the 
repeats are displayed (153). Group A is represented by the catfish herpesvirus in which 
the direct repeats are present at the termini. The herpes samiri virus comprises group B 
where terminal sequences are directly repeated several times at both ends. In group C, 
the direct terminal repeats are smaller than 100 bp (Epstein Barr Virus). The varicella 
zoster virus represents group D where terminal sequences at one terminus is repeated 
internally in the opposite orientation. In group E, sequences from both termini are 
repeated in an inverted orientation and are juxtaposed internally dividing the genome into 
two components. Each consists of unique sequences flanked by inverted repeats. Herpes 
simplex virus and the human cytomegalovirus represent group E. Lastly, group F 
contains sequences at two termini not identical. This group, represented by the tupaia 
herpesvirus, is neither repeated directly nor inversely (reviewed in 153).
The HCMV genome has been classified as a class E genome because the 
reiterated sequences occur at the termini and within the genome in the opposite 
orientation separating two different sequences into unique long (UL) and unique short 
(US) domains. The two domains can be rearranged or inverted to produce four different 
isomers of the HCMV genome. The genome of HCMV (AD 169 strain) has been 
sequenced in total (24) and contains 208 predicted open reading frames (ORFs). The 
genome is divided into seven conserved sequence blocks (A to G) arranged in the order 
ABCDEFG (125). Although other herpesviruses contain sequence blocks, the 
arrangement or order is slightly different. The products from the conserved blocks
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6appear to function in DNA replication, DNA repair, nucleotide metabolism, or virion 
structure (125).
Clinical isolates as well as laboratory-adapted strains exist for HCMV. Previous 
studies show that differences in virulence among the various strains is dependent upon 
factors such as the inclusive genome sequences, cell tropism, and the presence of specific 
glycoproteins. Clinical isolates from patients as well as the low-passage Toledo strain 
contain greater than 13 kbp more of DNA than the high-passage AD 169 and Towne 
strain (21). The 13 kbp region codes for putative glycoproteins. It has been observed in 
studies on cell tropism that clinical HCMV isolates have increased growth properties in 
endothelial cells compared with growth in fibroblasts (64,211). In experiments which 
detect infectious foci, clinical isolates were able to replicate well as exhibited by spread 
in endothelial cells, but AD 169 and Towne strains did not induce infectious foci at all 
(172).
Pathogenesis of HCMV Disease
HCMV exists as a ubiquitous pathogen and a majority of the human population is 
serologically positive by young adulthood. Asymptomatic lifelong persistence is one of 
the striking characteristics of HCMV in an immunocompetent host. An unresolved issue 
regarding the state of HCMV in the normal individual is whether the virus produces low 
levels of infectious virus which is considered a chronic state, or if the virus truly lies 
latent producing no detectable infectious virus (15,19, 171). Viral persistence is of great 
concern since reactivation of HCMV in immunocompromised patients is an increasing 
problem.
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7HCMV persistence has been proposed to occur in macrophages and endothelial 
cells (reviewed in 42). Monocytes/ macrophages and endothelial cells are key 
participants in latent and acute infection from HCMV. In seropositive individuals, the 
source of virus is peripheral blood mononuclear cells (PBMCs). HCMV is transmitted to 
patients through the transfusion of the leukocyte fraction of peripheral blood. In patients 
with acute disease, HCMV is isolated from mononuclear and polymorphonuclear cell 
fractions. Separation of the PBMC population has resulted in the identification of 
monocytes as the predominant HCMV infected cell type (42,171). Ordinarily, HCMV 
natural infection of the PBMCs is infrequent and it is generally rare to find a productive 
infection in peripheral blood cells such as monocytes. When infection is observed in 
monocytes, however, it is low in frequency and viral expression is limited to immediate 
early events (171). Monocytes, therefore, are thought to both carry and disseminate 
virus evading the immune system by restricted gene expression. The differentiation of 
monocytes into macrophages may influence the ability of virus to replicate in these cells 
(177). In macrophages, HCMV infection is evident by the detection of virus and late 
viral gene expression (170). Epithelial, endothelial, and neuronal cells are productively 
infected with HCMV during an active infection. Vascular endothelial cells are another 
potential site for HCMV persistence (42). In vitro infection of monocyte derived 
macrophages can transmit virus to cultured endothelial cells via haematogenous seeding 
of endothelial cells. In particular, microvascular endothelial cells form the interface 
between peripheral blood and the underlying tissue. The interactions between these cell 
types may mediate the HCMV persistence as well as viral dissemination.
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8An HCMV primary infection is commonly initiated during childhood first 
infecting the ductal epithelial cells of the salivary gland. Transmission frequently 
transpires via person to person contact (e.g. urine, saliva). Virus is present and likely shed 
from the bodily secretions of a seropositive adult through tears, semen, cervical and 
vaginal excretions, breastmilk, blood, feces, and oropharyngeal secretions (reviewed in 
1S). In a healthy host, a clinical manifestation of the virus is a rare occurrence (reviewed 
in reference 125). Due to the in vitro properties of the virus, such as restricted cell 
tropism, limited cell to cell spread, and slow replication, pathogenicity often goes 
undetected. This also provides evidence for efficient immunity within the host. 
Symptoms characteristic of a common cold have been documented in subclinical cases. 
More severe cases, less common though, include a syndrome much like mononucleosis 
although not EBV derived. Fever, myalgia, pneumonia, hepatitis, and aseptic meningitis 
have also been recorded as occurring as a result of a primary infection or reactivation in a 
seropositive healthy individual.
As mentioned previously, the virus cohabitates with a seropositive 
immunocompetent host for life and it is possible that no virus is ever detected. However, 
in the case of individuals who are immunosuppressed, a primary infection as well as 
reactivation of HCMV can occur resulting in a severe clinical outcome. A HCMV 
infection/ reactivation either in a newborn not yet immunocompetent, or 
immunosuppression in transplant recipients, cancer patients, and AIDS patients may lead 
to cases of severe HCMV infection (reviewed in reference 15). In the case of fetal 
HCMV infections, the virus is acquired through crossing the placental barrier. This 
infection is considered one of the most prevalent congenital viral infection in humans.
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9Approximately 40,000 of newborns per year in the United States are infected and a 
significant percentage of the infants have long-term neurological damage (15). The 
seriousness of the viral infection is largely dependent upon the viral inoculum supplied 
by the mother, the virulence of HCMV, and the gestational age at the time of viral 
infection. HCMV intrauterine infection causes neurological damage to the fetus and thus 
accounts for the majority of the morbidity observed (15). While hearing loss is the most 
common neurologic abnormality, mental retardation and chorioretinitis have also been 
documented. Progressive hearing loss in the early years of life is likely evident of an 
ongoing CNS infection. Other symptoms occur as well, which include 
hepatosplenomegaly, thrombocytopenia, microcephaly, chorioretinitis, and hepatitis (15).
In allograft recipients, HCMV is a significant pathogen and contributes to disease 
not only in the transplantation process, but also in the post-transplantation period.
Greater than 60% of solid organ allografts, cardiac and hepatic in particular, develop 
HCMV infection (40,41). This may originate from the transplanted organ (54). As 
previously mentioned, blood products from transfused blood are an additional source of 
infection. Seropositive donor to seronegative recipient is the most common cause of 
primary infection resulting in severe HCMV infection with obvious HCMV disease. In 
the post-transplantation period, the level of immunosuppression influences the outcome 
of HCMV infections. Therapies directed at the elimination of T-lymphocytes, namely 
antithymocyte globulin and monoclonal antibodies directed at CD3+ lymphocytes in 
renal transplant recipients, have been associated with more frequent and severe HCMV 
infection (15,26,156).
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The lack of survival of the transplanted graft has been associated with HCMV 
infection; in particular, a decreased graft survival in renal transplantation due to 
glomerulopathy (31). Cardiac graft recipients often develop coronary artery 
atherosclerosis linked to infection by human CMV (183). In bone marrow recipients, a 
complex relationship is thought to exist between HCMV infection and graft versus host 
disease (GVHD). This theory, however, remains debatable. The incidence of HCMV 
infection post bone marrow transplant ranges from 32% to 70% (15).
HCMV is the most important opportunistic infection encountered in patients with 
AIDS. The invasiveness of an HCMV infection is inversely proportional to the 
peripheral CD4+ lymphocyte count (130, 143). HCMV infection in the lungs, central 
nervous system (CNS) (reviewed in reference 222), and gastrointestinal tract (GI) are the 
three main organs most frequently reported. Pneumonitis is one of several life- 
threatening infections in AIDS patients. CMV retinitis is the primary manifestation of a 
CNS infection and the potential for severe loss of sight is likely if left untreated. 
Encephalitis has also been described after a CMV CNS infection. When localized in the 
epithelial tissue of the GI tract, HCMV has been implicated as the etiologic agent in the 
wasting syndrome characterized by rapid weight loss as well as excessive vomiting (98).
The fact that HCMV is widely disseminated is well documented, with HCMV 
being present in virtually all organs of the infected host (reviewed in reference 15). 
Monocytes appear to be the primary carrier of HCMV in the host. Virus replication is 
targeted to epithelial, endothelial, and glial cells (125). Microscopically, the cells appear 
large with decreased cytoplasm and a large nuclei. The nuclei, in most instances, show
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marginated chromatin and notable intranuclear inclusions surrounded by a clear halo.
The numerous inclusions are often referred to as “owl’s eyes” (15).
The role of monocytes and macrophages in CMV infection have been largely 
characterized in the murine model of CMV. Stoddart et al. showed that murine 
cytomegalovirus (MCMV) infected monocytes may be functional in disseminating the 
virus to the spleen, liver, and lung (197). Macrophages have been implicated as being the 
site of productive viral replication and in the latency of MCMV (122, 146). Macrophages 
infected with CMV are also known to produce cytokines with antiviral activity. These 
include the tumor necrosis factor alpha (TNFa), interleukins (IL)-ip, -6, -8, -12, and 
interferon (IFN)-a/3 (reviewed in reference 19, 125, 137, 157). The role of macrophages 
in the production of IFN a/p provides direct antiviral activity against CMV in the early 
stages of infection, however this does not result in virus elimination. Therefore, while 
the production of cytokines via macrophages is advantageous for the host, the role of the 
macrophage in harboring infectious virus for spread gives this cell type a dual role.
Which of the dual macrophage roles win out in the outcome of infection is dependent 
upon multiple factors.
One important factor in the role of macrophages in response to viral infection is 
interferon. Generally, interferons (IFNs) are cytokines that render cells resistant to viral 
infection, regulate cell growth, and differentiation (reviewed in reference 207). IFNs are 
divided into two classes based on their ability to bind distinct receptors: Type I or IFN 
alpha/ beta (ot/P) and type II or IFN gamma (y). IFNs also induce distinct but 
overlapping sets of genes in target cells via activation of latent cytoplasmic factors by 
phosphorylation rendering them active and functional within the nucleus. IFN a
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stimulates signal transducers and activators of transcription (STAT) phosphorylation in 
the cytoplasm. The phosphorylated STAT proteins are then translocated into the nucleus 
where they form an interferon stimulated gene factor (ISGF)3 complex and bind the 
DNA sequence interferon stimulated response element (ISRE). IFN y, on the other hand, 
stimulates a different cytoplasmic complex initiating phosphorylation and translocation 
of the gamma interferon activation factor (GAF) complex to the nucleus. GAF then 
binds the DNA sequence referred to as gamma interferon activation site (GAS). Whether 
stimulated via type I or type II IFN, the result is induction of genes that initiate an 
antiviral state in response to viral infection.
Although the activation of cellular genes via IFNs function in antiviral defense, 
studies show that human viruses can inhibit this step. In an adenovirus infection, the 
El A gene product can interfere with the DNA-binding of interferon stimulated gene 
factor (ISGF)3 (58). Therefore, the transcriptional suppression of cellular interferon 
stimulated genes (ISG) results. The infection of cells with mutant El A deficient 
adenovirus can cause the activation of ISRE-containing genes. HCMV infection can 
complement El A mutants, however is unable to alter IFN cx/p regulated ISGs (131). 
Instead, HCMV infection increases the activation of ISRE controlled ISG54 gene without 
de novo protein synthesis. In this study, a novel transcription complex is induced in 
response to HCMV infection (131). An interferon regulatory factor (IRF)-3 in complex 
with CREB binding protein (CBP) is called the cytomegalovirus-induced interferon- 
stimulated response element binding factor (CIF) is formed in response to HCMV 
infection.
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IFN-y, plays a role in the differentiation of monocytes to macrophages. This 
cytokine component, in addition to TNFa, was shown to render macrophages fully 
permissive for HCMV replication (177). It appears that HCMV takes advantage of two 
major cytokines with antiviral activity to obtain a specific state of activation in 
macrophages that allows for unrestricted replication of HCMV (177).
The host immune response to murine and human CMV has been studied 
extensively (reviewed in reference 19). Both specific as well as nonspecific immune 
surveillance mechanisms are employed in response to CMV. In murine CMV, natural 
non-specific immunity controls virus replication in acutely infected mice. At the 
inception of a CMV infection, natural killer (NK) cells provide the innate immunity by 
controlling virus until the specific immune arm arrives (125). Natural killer (NK) cells 
non-specifically provide a significant defense against CMV. Neutralizing antibodies do 
not play a significant role in the reduction of virus. However, when neutralizing 
antibodies are administered to animals, protection seems to occur naturally when 
newborns suckle immune mothers (125,118). In the presence of antibody, HCMV is 
transmitted, but the extent of disease is very mild. Cell-mediated immunity, via cytotoxic 
T-cells (CTLs) in particular, plays a large part in the clearance of virus in murine CMV.
In humans, the presence of CMV-reactive CTLs, primarily specific to the pp65 and 
ppl50 tegument phosphoproteins correlates with CMV protection (125,150). CD4+ T- 
cells also play a pivotal role in controlling viral replication in the salivary glands (80, 81, 
125).
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
14
Antiviral therapies for treatment and prophylaxis of HCMV
HCMV disease ranges from mild to severe which is largely dependent upon the 
immune state of the host at the time of primary infection or reactivation following 
latency. Individuals armed with an intact immune system may develop cold symptoms or 
at most a mononucleosis-type syndrome. For a host immunosuppressed by AIDS or 
transplant therapy, a CMV infection could become life threatening. Several 
chemotherapeutic treatments have been utilized to treat the infection (reviewed in 
reference 15). These agents include leuokocyte interferon, interferon stimulators (i.e. 
pyran copolymer), transfer factor, as well as nucleoside drugs such as vidarabine, 
iododeoxyuridine, fluorodeoxyuridine, cytosine arabinoside and adenine arabinoside 
have been administered. However, due to an insignificant advantage clinically or 
extreme toxicity to the patient, these methods are no longer in use.
Acyclovir or ACV, active against other herpesviruses such as EBV, HSV-1, HSV- 
2, and VZV, was one of the first candidate treatments. The guanine nucleoside analog 
utilizes the viral thymidine kinase (TK) to phosphorylate acyclovir to its monophosphate 
form and cellular enzymes then act to phosphorylate the monophosphate form to its 
triphosphate form. The triphosphate form of acyclovir lacks a 3’ hydroxyl group thereby 
blocking viral DNA replication by chain termination. Therapies used for CMV require a 
different mode of action because a viral thymidine kinase enzyme is not encoded by 
CMV (15, 166).
Two primary therapeutic agents in the treatment of CMV infection were 
ganciclovir (GCV) (DHPG- [9-(l,3 dihydroxy-2-propoxymethylguanine]) and foscamet 
(phosphonoformate). GCV is widely used to treat HCMV infections and has been used
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in cases of HCMV pneumonitis, hepatitis, retinitis, colitis in AIDS patients, in addition to 
CMV infection in allograft recipients (166). The activity of GCV depends upon the 
virus-controlled initial phosphorylation in infected cells, however does not depend on the 
thymidine kinase of other herpesviruses (166). The UL97 open reading frame (ORF) in 
HCMV encodes a protein kinase that directs the phosphorylation of GCV to its 
monophosphate form (198).
Although GCV is widely used to treat HCMV infection, it has been associated 
with significant leukopenia and thrombocytopenia in some patients. As intravenous 
administration became toxic over time, GCV was used only in life-threatening infections 
of HCMV and an oral formulation later became available which decreased toxicity.
Foscamet inhibits viral DNA polymerase function and recent evidence shows that 
it also inhibits hepatitis B virus polymerase and the HIV reverse transcriptase (15, 166). 
Only for life-threatening infections is foscamet now used (15). Prolonged treatment of 
GCV or foscamet may result in resistance. Resistant strains contain mutations in the 
DNA polymerase gene (UL54) or in the UL97 open reading frames which encodes a 
phosphotransferase required for phosphorylation of GCV to its active form (11, 109, 174, 
198, 225). In vitro and in vivo evidence exists for increased effective treatment of GCV 
and foscamet over any of the previously mentioned agents.
New targets for antiviral drugs are currently being developed. A serine protease 
(UL80 ORF) is required for the formation of nucleocapsids. Since all herpesviruses 
contain the ORF for a serine protease, a broad spectrum antiherpesvirus drug is a 
possibility. The DNA processivity (UL44) factor, functional in viral DNA replication, is 
also under consideration (reviewed in reference 15, 44).
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Vaccines
Currently, no all-inclusive vaccine exists for protection against human 
cytomegalovirus. A live attenuated laboratory strain, the Towne strain, was used in the 
initial studies to prevent CMV disease in renal transplant patients (144). The virus was 
shown to be immunogenic in these patients, caused no CMV-associated disease, and 
failed to reactivate after the patients were immunosuppressed (114), (reviewed in 
reference 2). Either of the strains, Towne or AD 169, was administered in normal 
seronegative individuals inducing both neutralizing antibodies and cell mediated 
immunity (132, 144). Protective immunity against a wild-type challenge, however, was 
unsuccessful although some effects were decreased. There has been some reservation in 
the use of a replicating viral vaccine for the prevention of HCMV disease. A primary 
concern is the possibility of vaccination of women of childbearing age with a replicating 
and/or teratogenic virus (IS).
Recently, the focus of HCMV vaccination development has turned toward 
subunit vaccines. One aspect of development involves the production of HCMV proteins 
from recombinant expression systems. A large effort has been directed toward the CMV 
major envelope glycoprotein B (gB, UL55) (16, 125). The immunogenicity of gB has 
been demonstrated in experimental animals as well as in a study involving some humans 
(145, 179). Species specific protective immunity has been documented in mice treated 
with mouse CMV gB and guinea pigs treated with guinea pig CMV gB (55). The use of 
a subunit vaccine brings about some concerns because of the potentially different 
pathogenetic mechanisms in different populations (Reviewed in reference 15). For 
women of childbearing age, immunity which induces both a cellular response and the
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production of neutralizing antibodies elicited by gB would mean protection from a 
possible congenital infection. In the case of allograft patients, CTL activity is closely 
associated with outcome, therefore a subunit vaccine may include a dominant CTL target 
such as pp65 (UL83). The pp65 tegument protein ORF (UL83) within expression vector 
is a candidate DNA vaccine. Mice infected intramuscularly with pp6S constructs 
resulted in a primarily humoral response in 60 % of mice injected (138).
The Virus Growth Cycle
General Aspects of the Replicative Cycle 
The replication cycle for CMV is slow as compared to other herpesviruses. While 
HCMV requires 48-72 hours to produce detectable levels of progeny virus, HSV and 
VZV require 18-20 hours and 8-16 hours, respectively (15). The replication of HCMV 
can be detected as early as 15 hours postinfection in human fibroblasts. Unlike other 
herpesviruses, CMV fails to shut off host cellular metabolic processes. Instead, several 
studies have shown that CMV stimulates the synthesis of cellular protein, RNA, and 
DNA (29). It has been proposed early on that CMV DNA synthesis is dependent on 
cellular DNA synthesis (125,196). This issue has not yet been resolved.
Attachment and Penetration
HCMV glycoprotein makeup is much more complex than other herpesviruses. As 
the largest herpesvirus to date, the putative glycoproteins predicted far exceed any other 
herpesvirus. The amino-acid sequence of the laboratory adapted strain, AD 169, shows 
greater than 54 ORFs with glycoprotein characteristics (24, 32). Clinical isolates such as
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the Toledo strain contain an additional 13 ORFs which may encode glycoproteins. To 
date, however, only gB (UL55), gH (UL75), gL (UL115), gO (UL74), gp48 (UL4), 
GCF33 (UL33), gM (UL100) have been characterized as glycoprotein spikes (32,72, 73). 
Each appears to have roles in HCMV entry into cells. Currently, only the envelope 
glycoprotein gB (gpUL55) has been extensively characterized (32, 125).
Several virus-cell interactions between HCMV and the infected cell have been 
defined with the majority of information derived using cultured fibroblast cell lines, 
although HCMV is capable of infecting distinct cell types of diverse lineages, including 
endothelial, epithelial, neuronal, glial, monocyte/ macrophage, and smooth muscle cells 
(reviewed in reference 5). In vitro studies show that human fibroblast cells express the 
viral receptor at significantly increased quantities over either epithelial or endothelial cell 
types. Also, fibroblasts are more efficiently infected in vitro than those cell types 
previously mentioned (135).
To infect cells, HCMV must first cross the host cell plasma membrane. Virus 
entry occurs at the cell surface in a two step process in which the virus must attach to the 
host cell followed by the penetration of the virus into the cell. Receptors are widely 
distributed on several different cell types (102, 135). Putative receptors have been found 
in both permissive as well as nonpermissive cell types. One cell surface component that 
is utilized by HCMV in at least two cell types is the heparin sulfate proteoglycans 
(HSPG) (33). gB and gpULlOO (a component of the gcll complex) have heparin binding 
ability. Heparin binding is loose and can be dissociated easily. This step is referred to as 
“low affinity binding”. Therefore, a more stable association with the cell surface is 
required via interaction with a second “high affinity” protein receptor (176). CD 13, a
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cellular aminopeptidase, is a candidate for a “high affinity” binding receptor. The viral 
glycoprotein to which CD 13 interacts is not yet known.
Two additional cell surface proteins have been implicated in the HCMV entry 
pathway, more specifically, at penetration. HCMV virions recognize a 30-34 kDa protein 
called annexin II belonging to a family of proteins involved in a number of membrane 
fusion events (32,226). A cellular 92.5 kDa protein is the proposed receptor for gH in 
the HCMV fusion process (84). Viral envelope proteins that may mediate binding to the 
cell surface remain uncharacterized and no direct genetic evidence of specific function 
for any HCMV glycoprotein is available to date (reviewed in reference 16). gB as well 
as other viral envelope glycoproteins are candidates for binding to heparin (33). Once 
the viral glycoprotein binds the cellular heparin sulfate receptor, an aminopeptidase 
called CD 13 increases the stable binding before penetration (176). microglobulin may 
also act as a bridge between viral glycoproteins and the cellular receptor (32). Fusion of 
the viral envelope with the plasma membrane marks the initiation of penetration. In 
HSV, gH appears to be essential for viral penetration (85). Studies utilizing HCMV gH- 
specific monoclonal antibodies have indirectly shown that the HCMV gH glycoprotein is 
most likely functional in virion/plasma membrane fusion (85). gH participates in the 
entry process in concert with other glycoproteins. The gCin complex, a 240-kDa protein, 
is a heterotrimeric disulfide-dependent glycoprotein complex (gH/gL/gO), consisting of 
three glycoproteins found in the virus envelope (72. 73). gH (gpUL75) is thought to 
function in entry and cell-cell spread, however, its cellular receptor is unknown (16, 125, 
72, 73). gL (gpULl 15) possesses a chaperone-type function required for the proper 
processing and targeting of gH (16, 72). gO (gpUL74) is the most recently characterized
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component of the gCm complex. The function of the tripartite complex in the viral life 
cycle is not well defined.
Immediate-early gene expression
In HCMV gene expression, the resulting proteins are produced in a very ordered 
and sequential manner, and as such are divided into three major classes based on the time 
of expression after viral infection in cell culture (36, 215, 216). In the sequential 
expression of the HCMV genes, the immediate-early (IE) genes are the first to be 
transcribed. The IE genes require no prior viral protein synthesis for expression but 
instead rely on the pp71 (UL82) virion transactivator as well as host cellular factors for 
expression (199, 200). The IE proteins serve as regulators of early gene expression. The 
IE genes are derived from various regions on the HCMV genome. In addition to the 
major IE locus (UL122-123), other genes expressed at IE times include UL36-38, TRSl- 
IRS1, and US3 (28, 99, 191, 192, 185, 188, 215, 221).
The major immediate-early promoter (MIEP), upstream of the major IE locus, 
functions in the activation and expression of the MIE gene region. The strong enhancer 
region within the promoter is quite powerful and is regulated by the 5’ sequences 
containing repeated elements, that include cellular transcription factor binding sites 
within the MIEP (reviewed in 125). The repeated elements are referred to by their sizes 
as 16, 18, 19, and 21 bp repeats (14, 201). The corresponding proteins found to bind the 
repeats include NFkB and CREB for the 18 and 19 bp repeats, respectively (125). The 
transcription factor YY1 binds the 21 bp repeat (97). Among the known or putative 
binding sites in the MIEP are the TATA box, API, CCAAT or C/EBP, SPl, TFIlD/TBP,
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
p53, and retinoic acid. The immediate-early gene locus enhancer region of simian and 
murine CMV are almost indistinguishable from the HCMV MIEP (125).
The most abundant of the IE gene products arise from a single locus referred to as 
the major immediate early (MIE) region between 169 kbp and 175 kbp in the HCMV 
genome (reviewed in reference 125). Of the IE gene transcripts, two most notable (/el 
and ie2) arise by differential splicing of a single transcription unit. Together, they share 
exons I, 2, and 3 and the subsequent protein products [IE1 or IE72 (UL123) and IE2 or 
IE86 (UL122)] share the 85 N-terminal amino acids (186). The IE1 gene product is a 72 
kD protein of 491 amino acids from exons 1, 2, 3, and 4 of the ieMiel gene locus (125, 
186). The second gene product, from the IE2 gene region, is an 86 kD protein of 579 
amino acids It differs by virtue of a spliced transcript that includes exon 5 instead of 
exon 4 present in the iel transcript (192, 193). From the iel region, other transcripts are 
expressed such as the 55 kD protein o f425 amino acids generated as a result of intron 
removal from exon 5 (193, 187). A nonspliced transcript from within exon 5 produces a 
gene product of 338 amino acids only observed at late times in infection (148, 188, 193). 
Shortly after infection, the 72 kD and the 55 kD proteins are synthesized. A 38 kD, the 
86 kD, and the 97 kD are produced at approximately 2.5 hours after virus adsorption. 
Additional genes with regulatory functions are expressed at immediate-early times.
These include: TRS1 and IRS 1 which are highly homologous and appear to have an 
overlapping function in HCMV DNA replication in transient assays (185). UL36,37 
products act as transactivators and are functional in DNA replication in transient assays 
(28). Both IRS1/ TRSl and UL36-38 are members of the US22 gene family. US3 has
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sequence similarity to glycoproteins and may have a role in immune escape during 
HCMV infection (28,221).
Functionally, the IE72 and the IE86 proteins play a major role in the regulation of 
the MIEP as well as in early promoter activation. Several studies support the roles of 
IE72 and IE86 in the positive and negative regulation of viral gene expression (38, 94). 
The role of IE72 appears to be in activating expression of the iel/ie2 enhancer; 
specifically by the self stimulation of the MIEP via the transcription factor binding site of 
NFkB (126). IE86 represses expression of the IE72/IE86 from the MIE gene locus by 
binding the cis-repression signal (CRS) (25). Although viral gene expression from the 
MIE locus is reduced at early times after infection, expression returns late in infection 
(188). Equivalent nuclear phosphoproteins with transactivation function have been 
observed in other herpesviruses (4, 86).
The expression of subsequent kinetic classes is also regulated through the 
cooperation of IE72 and IE86 proteins in conjunction with other transactivators, such as 
UL112-113 as well as the previously mentioned UL36-38 and IRS1/TRS1 (180, 181). 
While IE72 has been shown to transactivate via protein-protein interaction, IE86 binds 
other proteins as well as interacts with DNA directly to mediate gene expression. IE72 
was found to associate with E2F-1, SP-1, and CRF-1 (61, 108, 113). IE86 plays a central 
regulatory role in the switch from IE to early gene expression (125). First, iel/ie2 
expression is shut off by repression of the MIEP via IE 86 binding to the CRS as 
mentioned previously. IE86 is quite indiscriminate in its association with host 
transcription factors and its protein-protein interactions have been shown to result in the 
activation of early gene expression. Evidence for direct interaction of IE86 with TBP,
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TFI1B, CREB, c-jun, and CBP has been established (18, 82, 103, 163,165). Although no 
direct interaction has been found with IE72, IE86 has been shown to synergistically act 
with IE72 in the activation of early promoters (86). The N-terminus and the C-terminus 
have been found important in the transactivation by IE86 (125). The effects of IE 1 and 
IE3 in murine CMV are analogous to IE72 (IE1) and IE86 (IE2) in HCMV (86, 119,
120).
Early Gene Expression
By current description, early gene expression requires the prior synthesis of IE 
gene products and occurs before viral DNA replication (180, 125). Early genes encode 
both structural as well as nonstructural proteins including enzymes involved in viral DNA 
replication (36, 215,216). Numerous transcripts are produced during the early phase. 
However, only some of the gene products are evident in the early phase and others are 
often not visible until late in infection. This substantiates the thought that early genes are 
transcriptionally and posttranscriptionally regulated. A DNA negative mutant of 
HCMV, ts66, was used to demonstrate that early RNA transcripts have differential 
patterns of expression post viral DNA replication (186). From these studies, the early 
genes have been subdivided into three subclasses based on expression at early and late 
times post-infection. The first class of early genes is transcribed early and down- 
regulated after viral DNA replication (i.e.- 2.7 kb RNA; located in the long repeat of the 
genome corresponding to the EcoFl O and W fragments in strain AD 169) (93, 186). The 
second class is expressed at constant levels throughout the course of infection [i.e.- 
(pol/UL54), (2.2 kb RNA/UL112-113)] (186). Lastly, the third class is expressed 
minimally early, but subsequent expression increases at late times [i.e.- (pp65/UL83,
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encodes lower matrix protein), (1.2 kb RNA; mapped within the EcoRI-0 fragment in the 
long segment of the viral genome in strain AD 169) (186). A more recent set of studies 
has provided strong support for these observations by showing that the expression of 
three early RNA transcripts is quite different (180).
Numerous studies on several HCMV early promoters have demonstrated the 
specific mechanisms necessary to mediate promoter activation for early gene expression: 
in particular, the sequence requirements and the transacting factors involved (29, 38, 90, 
95, 163, 164, 182, 184). Several assays have been widely used to determine the role of 
each of the HCMV major IE proteins in early promoter activation. One strategy 
comprises individual cDNAs for each protein that act as effectors under the control of a 
strong promoter such as the MIEP (38, 163, 184, 189). The target plasmid contains a 
hybrid promoter-reporter vector with the chloramphenicol acetyltransferase gene or the 
luciferase gene being more commonly used (23, 189). Transfected into fully permissive 
human fibroblast cells, a measure of promoter activation is assessed following 
cotransfection.
To date, experiments performed to study the transcriptional regulation of early 
gene expression propose that the IE86 protein alone or in conjunction with IE72, UL36, 
UL37, TRSl, IRS1, UL112-113 or US3 gene products (27, 88, 180, and 23) is required 
for early promoter activation. By the method described above, both IE72 and IE86 were 
shown to be required for maximal promoter activation on several early promoters (22, 38, 
184, 189). The IE proteins activate the pp65 promoter through an octamer sequence 
(ATTTCGGG) (38). The polymerase promoter, also activated by IE transactivators, 
utilizes an inverted repeat 1 (IR1) element for its activation as demonstrated by a mutated
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ER1 disrupting binding and adversely affecting its activation (90). More recently, Chau 
et. al. showed that the US 11 promoter is not only synergistically activated by IE 1 and 
IE2, but is further stimulated in the presence of the phosphoprotein pp71 (23). The 
promoter utilizes the CRE and ATF sites which together cooperate to regulate the US 11 
promoter in HCMV infected cells (23). In addition, IE86 has been determined to be the 
major transactivator for at least three early promoters, the 2.7 kb, 1.2 kb and the 2.2 kb 
RNA promoters as the addition of IE72 alone did not significantly or only weakly 
increased the activation of the promoters (94, 103, 117, 184). When both IE72 and IE86 
were transfected simultaneously, a modest increase in activation by 1-3 fold over IE86 
activation was observed (180). Colberg-Poley et al. established the ability of other IE 
gene products such as US3, IRS 1/TRS1, and UL36-38 to alter viral and cellular gene 
expression (28). UL112-113, TRS1 and IRS1, which are required in ori-Lyt viral DNA 
replication, are also transcriptional activators that augment IE1 and IE2 mediated 
activation of early promoters (75, 88). Although a significant level of promoter activity 
was observed in the presence of the IE transactivators, full activation to mediate the 
regulatory cascade takes place through the addition of a variety of cellular transcription 
factors.
Spector et al. have studied three early promoters (2.7, 2.2, and 1.2 kb RNAs) that 
exemplify differential expression patterns as mentioned previously (93, 95, 180, 184, 
208). Through a series of well planned experiments, the promoters have been carefully 
studied to determine how each is regulated in early gene expression (180). The 2.7 kb 
RNA is detected at increased levels early in infection but decrease following viral DNA 
replication. The essential cis-acting sequences important for the regulation of the 2.7 kb
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RNA were determined via the generation of deletions and point mutations within the S’ 
regulatory sequences. S’ deletion mutants resulted in a stepwise reduction in activity 
(93). The cis-acting sequences from -113 to -106 (a palindromic octamer sequence) 
were similar to the consensus binding site for MLTF/USF transcription factors (94).
Point mutations in the MLTF/USF site decreased the inducible activity by 50 % in 
transfection assays using IE86 or HCMV as compared to wildtype. The identical 
mutations in gel shift analysis showed decreased binding affinity to the MLTF/USF site 
which thereby provided further evidence for its role in the 2.7 kb RNA promoter 
activation (94).
Unlike the 2.7 kb RNA the 2.2 kb steady state RNA levels peak by 8 hours 
postinfection (hpi) and remain constant throughout the course of infection. The presence 
of alternative splice sites yields four RNAs of 2.1, 2.2, 2.5, and 2.65 kb (227). By 
deletion mutations, Rodems et al. determined that promoter activation of this early gene 
requires sequences from -113 to -59 containing a weak IE86 binding site as well as the 
consensus sequence for the cellular factor CREB/ATF (TGACGTCA) (152, 163). Site 
specific mutations confirmed sequences between -72 and -61 (CREB site) were critical 
for activation by IE86 (152). The promoter sequence also formed a complex with in vitro 
translated ATF2/CREB and antibodies directed against ATF/CREB family members 
showed one binding factor: CREB (152). Activation of the 2.2 kb RNA promoter was 
therefore facilitated by CREB (152, 163).
Lastly, the 1.2 kb RNA is expressed at low levels early in infection and increase 
at late times, hence, a member of the third class of early RNAs. The promoter is 
activated indirectly by IE86 through an API site (174). 5’ deletion analysis revealed that
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a TATAA like element (CATAA) at -30 and an AP-1 binding site at -75 are important 
for promoter activation (208). The key role of AP-l and CATAA site was confirmed by 
the generation of specific point mutations in transient assays and gel shift assays. GST- 
fusion experiments in conjunction with coimmunoprecipitation experiments show that c- 
jun, junB, and ATF-2 bind IE86 (208).
Three different early promoters have been evaluated by similar approaches and 
clearly show that a combination of various IE proteins as well as cellular factors are 
necessary to activate the promoter sequences which regulate early genes. Transient 
expression assays in conjunction with protein-protein interaction studies in the 
identification of regulatory viral and cellular factors important for the regulation of early 
gene expression have correlated well (93, 94). HCMV early promoters are not ordinarily 
activated in uninfected cells or cells lacking the IE proteins. And further, it is clear that 
cellular transcription factors are insufficient for early promoter activation. Early 
promoters are not activated in HCMV infected cells until after the IE phase of gene 
expression begins. Therefore, it is the complex interplay between IE proteins and various 
cellular factors that are responsible for the vast diversity among early gene expression 
(190).
There have been numerous studies which address how HCMV transacting 
proteins influence the regulation of viral and cellular promoters (126, 186, 190). More 
recently, these studies have taken a leap toward a more accurate assessment of these 
regulatory events in the context of the viral genome. Jones and coworkers demonstrated 
that a region of the unique short (U,) component of the HCMV genome is dispensable for 
growth in cell culture (79). From these findings, a strategy was developed to insert the
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HCMV promoter-chloramphenicol acetyltransferase (CAT) gene constructs into the viral 
genome. In this way, sequences responsible for regulating HCMV at early and late times 
could be identified. RV134 is a recombinant virus which expresses the 3-glucuronidase 
gene under the control of the 2.7E promoter (79,96). The insertion of the HCMV 
promoter-CAT constructs into the transcriptionally barren intergenic region between the 
US9 and US 10 open reading frames using the recombinant virus provided a more precise 
way to study the promoter cis-acting elements that regulate HCMV gene expression 
during a natural infection (96). Kerry et al, were able to extend the characterization of 
the UL54 promoter by inserting the polymerase promoter, mutated in the IR1 element 
and the ATF-l element, into the recombinant virus (89, 90). UL54 regulation throughout 
the course of infection could then be assessed. The importance of the IR1 element in 
promoter activation at early times was confirmed, but the same element had no effect late 
in infection (88). The ATF-l site, however, when mutated, reduced UL54 promoter 
activity at both early and late times (89). These data showed that in vitro and in vivo data 
do not always correlate. In 1998, Rodems assessed the function the UL112-113 early 
promoter in the context of the viral genome (152). The ATF/CREB site was functional at 
early times only, while the IE86 site was required for modulating the levels of RNA at 
early and late times (152). Recently, the US 11 early promoter was examined by Chau in 
its natural context and found to utilize the CRE and ATF sites in the regulation of the 
US11 promoter in HCMV infected cells (23). Both elements were functionally important 
for promoter activation by IE proteins when assessed by deletion analysis. The 
mutagenesis of both sites revealed that full promoter activity requires the wildtype CRE 
and wildtype ATF sequences. Examined in the natural genomic context, mutation of the
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CRE or ATF site resulted in a significant reduction in RNA levels. The simultaneous 
mutation of the CRE/ATF sites rendered RNA levels undetectable. A different system 
has been used to assess the HCMV US 11 gene function in a natural infection utilizing the 
tet repressor system developed by Kim et al. (92). These studies demonstrated that a 
functional tet repressor was able to down-regulate expression from a US11 promoter 
containing repressor binding elements. Located in its natural position in the HCMV 
genome, the US 11 promoter was modified with varying numbers of copies of the 
repressor binding sequence. This allowed for the conditional expression of viral proteins 
of interest (190)
In the chapters to follow, the UL98 early promoter has been extensively 
characterized. The S’ regulatory region of the UL98 alkaline exonuclease gene was 
isolated and the specific cis-acting elements functional in UL98 gene regulation were 
determined. The results demonstrated that a CRE and gamma IRE binding sites within 
the UL98 promoter have an important role in transactivation by the viral regulatory 
proteins from the HCMV MIE region. The transcriptional transactivator CREB was 
found to bind the UL98 promoter CRE site in DNA/protein interaction studies. CRE and 
ATF sites have also been utilized by early promoters for UL54, UL112-113, and US11, 
Therefore, the employment of CREB/ ATF family members in the regulation of HCMV 
early gene regulation appears to be a recurrent theme. This seems to reflect a general 
mechanism in early gene activation and is not specific for a particular early subclass.
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Viral DNA Replication
Several proteins that play a role in CMV replication have been accurately 
predicted due to the similarities among other herpesviruses. Seven ORFs provide the 
necessary and sufficient viral proteins for viral replication (62). Among them are the 
origin binding protein (UL9) followed by the DNA polymerase (UL54), the processivity 
factor of the DNA polymerase (UL44), ssDNA binding protein (UL57), and the helicase- 
primase complex comprising three polypeptide subunits (UL105, UL102, and UL70) (6, 
125). The HCMV genome is approximately 229 Idlobase pairs (kbp) of linear double- 
stranded DNA. At approximately 4 hours after infection, the HCMV genome 
circularizes. Concatemers are formed and genomic inversions occur within the DNA. 
This is followed by the process of cleavage/packaging and seems to select the DNA 
termini derived from the S component rather than the L component into maturing capsids 
in one of four possible isomers (125). Viral DNA synthesis comes to a climax at 18-24 
hours and again at 60-80 hours postinfection. Orilyt (the lytic phase replicator of 
HCMV) replication requires the use of several other trans-acting factors. These include 
UL54, UL57, UL44, UL105, UL102, UL70, UL122-UL123 (IE1-IE2), UL36-UL38,
TRS 1/IRS 1, UL112-113, and UL84 (140, 141).
Late Gene Expression
Upon the initiation of viral DNA synthesis, late gene expression takes place 
producing primarily structural proteins. Due to the dependence on viral DNA replication 
and the need for a variety of transactivators produced at IE and E times, late gene 
expression requires a more complex regulation. Only a limited number of late genes
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have been studied to determine the regulation of late gene expression. Genes currently 
classified as true late genes include the pp28 (UL99) phosphoprotein (38, 89, 96), viral 
glycoproteins (48). the 40 kD protein from the IE2 gene region (77), and the UL94 gene 
(224).
The pp28 promoter has been extensively studied and IE proteins were insufficient 
for promoter function (37). Protein products from the US3 (24, 221) and UL36-38 (24, 
99, 200) gene regions also poorly activated the pp28 promoter. Therefore, additional 
viral proteins are required. No known consensus cellular transcription factor binding 
sites were found upstream of the CAP site. However, repeated sequences were found in 
the 5’ promoter region in both the direct and inverted orientation. Perhaps only these 
sequences are necessary to regulate late gene expression (125).
Unlike early gene regulation studies, to study late gene expression requires the 
use of whole virus in transient assays; the use of IE and E transactivators in transient 
assays has proven ineffective (37, 125). As a result, little is known about the specific 
transactivators responsible for the initiation of late gene expression in HCMV. Stasiak 
and Mocarski characterized the ICP36 late promoter and found that TRS1, part of the 
US22 gene family, in combination with EE1 and IE2 proteins could activate this late 
promoter (185).
Late gene expression has been studied extensively in HS V. The gC promoter is 
activated early and no proteins are expressed until after viral DNA replication (69). This 
seems to be characteristic of true late promoters. Both HSV and HCMV promoters are 
activated at early times when expressed independent of the viral genome (37). Late gene
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regulation studied using the HSV glycoprotein C (gC) was due to sequences near the S’ 
terminus of the gene (69, 154). The HSV gC gene contains sequences located in the 3’ 
portion of the promoter that require the context of the viral genome for regulating gC as a 
late gene.
Virion Assembly
The assembly of HCMV begins late in infection with the MCP/PAP capsid 
proteins (which carry the nuclear localization signal), translocating from the cytoplasmic 
space into the nucleus. Nucleocapsids accumulate in the nucleus and form a nuclear 
inclusion often recognized microscopically by the typical “owl’s eye” cytopathic 
effect(15). The nucleocapsids mature within a nuclear fibrillar network consisting of 
viral structural proteins and DNA. The formation of pre-B capsids into B capsids follows 
as the preformed capsids prepare to receive the DNA. The DNA is cleaved and 
packaged enzymatically in unit length from the replicating form. Capsids, now properly 
packaged with DNA, acquire the tegument proteins and become enveloped (50). While 
HSV envelopment takes place at the innemuclear membrane, cytoplasmic envelopment 
followed by egress has been reported for CMV and has been observed in CMV infected 
cells (50). An envelopment/ deenvelopment mechanism has also been suggested but has 
not yet been confirmed (125). The different pathways that virus can take during egress is 
not yet completely understood for the herpesviruses.
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Herpesvirus Alkaline Nuclease
HSV-1 and HSV-2 viral alkaline nucleases were first described in 1968 by 
Morrison and Keir (128) and were expressed and mapped within the same viruses over 10 
years later (129, 147). The mRNA has been mapped to a 2.3 kb mRNA and is a member 
of a group of unspliced 3’ coterminal mRNAs (154). DNA sequence analysis revealed 
that the ORF, designated UL12, encodes a 626 amino-acid phosphoprotein of 85 kDa, 
which exhibits both exonuclease and endonuclease activities (47).
The HSV alkaline nuclease was not considered essential for viral DNA replication 
but may be functional in the processing of complex replicative DNA intermediates prior 
to their packaging into capsids (116,217, 218). Herpesviruses contain large concatamers 
of DNA that are cleaved into unit-length genomes for packaging into preformed capsids. 
The DNA containing capsids are then transported from the nucleus to the cytoplasm, 
enveloped, and released from the infected cell. The HSV-1 UL12 gene product has been 
implicated in virion maturation, but its role in DNA processing is still not clear (217, 
218). For HSV-1, it is thought that the nuclease functions in processing replicative DNA 
intermediates prior to packaging into capsids (116, 218). A deletion mutant (named AN- 
1) of the HSV-1 alkaline nuclease fails to induce alkaline nuclease activity in infected 
cells (167). The ability to synthesize viral DNA remains; however, the mutant fails to 
produce infectious virions efficiently and therefore, steps in genome maturation and 
encapsidation are defective (167). It has been proposed that the defect caused by AN-1 
results in the inability to resolve or '‘debranch” recombination intermediates (115, 116, 
167).
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The UL98 gene of HCMV shares similar nucleic acid sequence homology as well 
as some amino acid sequence homology with the alkaline nucleases of other known 
herpesviruses (24). The exact function of the alkaline nuclease during infection is not 
clear. Sheaffer et. al. confirmed by in vitro activity that the alkaline nuclease of HCMV 
is the homologue of the HSV-1 alkaline exonuclease (169). More recently, an 
assessment of the biological role of HCMV UL98 revealed that UL98 AN can 
functionally substitute for HSV-1 AN (167). In addition, a defect in the HSV-1 AN is 
fully compensated by the HCMV AN when provided in trans (47).
The UL98 ORF shares a 3’ coterminus with the ORFs of HCMV UL93-UL99 
(I, 223). The HCMV UL98 ORF encodes an mRNA of 3.0 kilobases (kb) that is 
synthesized at early times of infection, and mRNA levels increase significantly following 
viral DNA replication (1). The UL98 gene product is a translated protein which migrates 
from S8-6S kD and is expressed at approximately five hours postinfection (1, 169). The 
translated protein is both phosphorylated and glycosylated and localizes to the nucleus 
late in infection and has been identified as a component of extracellular viral particles 
(169).
As previously mentioned, the early genes are divided into three subclasses (Early 
-1 or El, E2, or E3) based upon the expression of the transcripts following infection.
The complex regulation of the early phase has prompted extensive studies of the 
upstream 5’ regulatory sequences necessary for the control of this complex class of 
genes. These studies have revealed the cis-acting sequences that confer promoter 
responsiveness to IE proteins as well as trans-acting factors that likely play an important 
role in the regulation of early genes. The HCMV UL98 early gene falls in the early
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subclass that is expressed at low levels early postinfection, but rapidly increases after the 
onset of viral DNA replication (1, 223). The kinetics of UL98 gene expression is similar 
to two other E3 genes: the pp65 phosphoprotein and the 1.2 kb RNA gene product (38, 
186, 208). For this reason, the S’ regulatory region of the UL98 gene was isolated and 
studied. The polymerase promoter has been studied extensively in the same laboratory 
and, as an early promoter (E2 subclass), was used as a basis of comparison and contrast 
(90).
To date, the HCMV UL98 5’ regulatory sequences have been described in two 
separate papers. Wing and Huang determined the initiation start site, the TATA box, and 
the CAP site via primer extension and northern blot analysis as well as the consensus 
binding sites for SRF (5’GATGTCC3’) at -152, E2F (5’TTTCGCCG3’) at -127 and 
CREB/ATF (5TACGTCAG3’) at -82 relative to the RNA initiation site (223). As 
mentioned earlier, the CREB/ ATF family of transcription factors are involved in the 
regulation of several viral early promoters (106). Both direct and inverted repeats were 
also found within the UL98 promoter (1). A DNAsis sequence data base search showed 
that elements for TCF-1 (5TCTGTT3’) at -59, SIF (5’GAGCTD’) at -43, and gamma 
interferon (5’CTGTATTD’) at -37 were present as well. The overall objective of the 
following studies is to determine how the HCMV UL98 promoter utilized its uniquely 
arranged response elements to optimally regulate the expression of this early gene. From 
these studies, we hope to obtain a clearer picture of the different mechanisms employed 
in early gene activation and regulation as observed in yet another early regulatory region.
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CHAPTER H 
SPECIFIC OBJECTIVES
The overall aim of this study was to determine the 5’ regulatory elements which 
function in the regulation of the UL98 early gene. The UL98 promoter contains six 
putative c/s-acting sequences upstream of the TATA box. In order to assess the 
functional role of each transcription factor binding site, an overlapping PCR mutagenesis 
approach was utilized for the generation of deletion mutations or substitution mutations at 
each site. The promoter regulatory sequences cloned upstream of a reporter gene were 
tested in transient transfection assays in the presence of viral immediate early (IE) 
transactivators or HCMV infection. Changes in promoter activity compared to the 
wildtype promoter due to mutations present provided insight into the cis-acting 
sequences that facilitate the process. The cooperative effort of two or more elements in 
UL98 promoter activation was examined by the generation of truncated promoters with 
the elements in question mutated in each promoter. To determine viral or virally induced 
transactivators that may physically complex with the cellular transcription factor binding 
sites, binding assays were carried out to identify the proteins that play a role in activation 
and facilitate UL98 promoter gene regulation.
The specific objectives of this study were:
1) To identify the UL98 5’ promoter region relative to the putative TATA box motif and 
the CAP site at +1. The UL98 alkaline exonuclease promoter region was isolated as a 
421 base pair DNA fragment. The strategy was to place the UL98 promoter 
sequences upstream of the chloramphenicol acetyltransferase (CAT) gene in a
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reporter construct. The activation of the S’ regulatory sequences was tested in 
transient transfection assays in response to the immediate early transactivators IE72 
and IE86 or HCMV'. The IE requirement for UL98 promoter activation was also 
assessed using a prototypical early promoter of the UL54 polymerase gene.
2) To generate mutations within the UL98 promoter via restriction endonuclease 
digestion or overlapping PCR mutagenesis. Deletions were generated by digestion 
with HindUl (AAGCTT) and a unique restriction enzyme. By this method, sequence 
removal 5’ to 3’ in a stepwise fashion could be accomplished. In the absence of a 
downstream unique restriction enzyme site, the insertion of an additional HindUl site 
was feasible. For targeting a mutation, putative c/s-acting elements were also 
changed using overlapping PCR to generate an EcoRl site (GAATTC). The resulting 
variant promoters were then tested for promoter activation in response to HCMV.
3) To determine the necessary transcription factor binding sites within the 5’ regulatory 
sequences which confer UL98 promoter responsiveness to viral or virallv induced 
proteins. Wild-type and mutant promoters were tested in transient transfection assays 
by cotransfection in the presence of IE expressing plasmids or in superinfection 
assays with HCMV.
4) To determine the transacting factors that form a complex with the transcription factor 
binding site bv analysis of protein-DNA interactions bv gel mobility shift assays To 
identify which proteins, viral and/or cellular, bind the elements within the UL98 
promoter, the DNA fragments of interest were radioactively end labeled and 
incubated with nuclear extracts containing DNA binding proteins. Competition 
studies were carried out to assess sequence specificity by the preincubation of excess
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unlabelled probes with mock or HCMV infected cell nuclear extracts. To examine 
specific protein binding, antibodies specific for proteins suspected as binding UL98 
sequence were employed in supershift assays.
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CHAPTER IH 
MATERIALS AND METHODS 
Cells
Primary Human Foreskin Fibroblast (HFF) cells were used for propagation of 
virus (Towne), transfection and superinfection assays, and the generation of nuclear 
extracts for gel mobility shift assays. Cells were grown in Minimal Essential Media 
Eagle (MEM) (Gibco BRL, Rockville, MD) supplemented with 0.03 % L-glutamine 
(Sigma, St. Louis, MO), 0.006 % Penicillin (Sigma, St. Louis, MO, and 0.01 % 
Streptomycin (Sigma, St. Louis, MO) Cells were incubated at 37° C, 5% CO2. HFF 
cells were passaged on a weekly basis.
Virus
Towne, a laboratory adapted strain of HCMV, was used exclusively for the 
studies throughout. For superinfection assays, 10 PFU per cell was used. Frozen stocks 
of Towne were used at a titer of 5 x 107 PFU per milliliter. For gel shift analysis, cells 
were infected at 10 PFU per cell with a stock titer of at least lxlO7 PFU per milliliter.
IE gene region plasmids and cDNAs
Plasmids able to express proteins from the HCMV major immediate early (IE) 
gene region 1 (pSVCC3), IE gene region 2 (pACC), and IE gene regions 1 and 2 (pSVH) 
were generated by R.M. Stenberg, Ph.D. and have been previously described (189). 
pSVOd was the vector used to construct the IE gene region plasmids. IE region 1 and 2 
cDNAs were also generated by R.M. Stenberg; however, were placed in the vector pSL 
(an expression vector that contains a Hindlll-EcoRI fragment of pcDVI, the Hindlll- 
EcoRI of the pLI vector, and the simian virus 40 early promoter 5’ to the Kpnl site)
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described in references (136, 189). pIE72kD cDNA and the pIE86kD cDNA contain the 
coding sequences of the major IE1 (72kD) and IE (86 kD) proteins, respectively (136, 
189).
AJal-C (pCBX8.i) plasmid
pCBX8.1 is an 8.1 kb BamHl to Xbal fragment of Xbal-C containing the pp28 
gene region. From this construct, a digestion from Pstl to A7ioI gave a subfragment of 
621 bp and a subsequent BsrFl digestion gave a subfragment of 421 bp which contains 
the UL98 promoter fragment.
pUL98CAT
To clone the upstream UL98 promoter, pCBX8.1, a plasmid containing the UL97 
and UL98 open reading frames (ORFs), was digested with Pstl and Xhol to isolate a 0.6 
kb fragment. Subsequently, a 421 bp (0.4 kb) fragment from -309 to +112 relative to the 
UL98 CAP site was isolated by digestion with BsrFl (CJrIOl- isoschizomer). The 
digested products were separated by acrylamide gel electrophoresis. The fragment was 
repaired by Klenow fragment and 12mer Hindlll linkers were added to the ends, cut, and 
purified through a 10% acrylamide gel. The fragment of 421 bp was cloned into the 
unique Hindlll site of a linearized pSVOCATd upstream of the CAT gene.
pdH309CAT
pdH309CAT is devoid of the 3' Hindlll site in pUL98CAT was used to generate 
the deletion mutants generated from the 5' Hindlll site to a unique 3' restriction enzyme 
site or an inserted Hindlll site. pUL98CAT was subjected to partial digestion with 
Hindlll The linear fragments were isolated on a 5% polyacrylamide gel, stained in 
ethidium bromide, and the linear products were isolated from the gel. The DNA was
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removed from a gel slice by electroelution, precipitated with ethanol, dried, and 
resuspended in sterile deionized water (sdH20). For confirmation of correct isolated 
linear fragment, one tenth of volume of isolated DNA was run on a 1.0% agarose gel.
The linear DNA fragment was Klenowed and religated at the unique HindIII site.
Positive constructs for 3' Hindlll knockout lost the ability to generate a 62 bp fragment 
when screened by digestion with Hindlll and Aval. The product containing only the S’ 
Hindlll site was selected by restriction enzyme digestion with Hindlll which now results 
in a linear fragment of 4.3 kb or 4,309 bp.
Deletion Mutants
To remove transcription factor binding sites 5' to 3', a linear pdH309CAT was 
digested with Hindlll at -309 and a restriction enzyme for a unique downstream site. We 
initially generated three deletion mutants. pdH309CAT was digested from -309 to -194, 
-136, or -106. Hindlll linkers were added to the fragments remaining (-194 to +3888, 
-136 to +3888, and -51 to +3888), which were then purified through a 5% acrylamide gel 
and prepared for religation. For the remaining deletion mutants, the Hindlll restriction 
enzyme site was inserted between transcription factor binding sites using an overlapping 
PCR mutagenesis strategy. To generate each new Hindlll site, four synthetic 
oligonucleotides (oligos) were generated and used as primers (see appendix m  for 
specific primer sequences) for the Hindm  insertions in two separate reactions. Two 
internal primers (b,c) contained the Hindlll site to be substituted, and the external primers 
(a,d) consisted of vector sequences necessary to amplify the altered promoter region. In 
the first reaction (100 ul volume), primers [(a and b) or (c and d)] (20 picomoles each) 
were paired (one internal and one external complementary) in the presence of lul of
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DNA template (1 nanogram per 1 microliter), lOx PCR buffer with (Gibco BRL),
10 mM dNTPs stock (2 ul to give I mM of each dNTP per reaction), and Taq polymerase 
(0.5 ul at 5 units per ul) to insert and amplify the restriction enzyme sites into the sense 
and antisense DNA strands separately. The products of reaction one were subjected to 
Klenow in a fill-in reaction and incubated at room temperature for 15 minutes. In a 
second reaction, two overlapping products were then incubated under the same conditions 
with the two external 5' (a) and 3' (d) primers to amplify a double stranded UL98 
promoter product with a Hindlll site inserted. All PCR reactions were carried out under 
the same conditions in a thermocycler (Cetus). PCR conditions were set at 94°C/ 1 
minute (denaturation), 55°C/ 1 minute (primer annealing), and 72°C/1 minute (extension) 
for 32 cycles followed by a soak setting of 4°C to maintain refrigeration temperature until 
processed. The final PCR products deleted to
-85, -64, -34, and -28 were digested with Hindlll, purified by electrophoresis, and cloned 
into pS VOCATd. Each deletion construct was tested in transient transfections in the 
presence of IE proteins or HCMV for changes in promoter activity as compared to the 
wildtype promoter construct (pUL98CAT).
Substitution Mutations 
Mutagenesis of pUL98CAT construct by overlapping PCR (as described in the 
previous section: deletion mutations) allowed for the replacement of targeted wildtype 
sequence with the restriction enzyme site EcoRl (GAATTC). The restriction enzyme site 
EcoRl was selected to disrupt the cis-acting element located within the UL98 promoter 
region. This not only introduced a mutation at the desired site, but also provided a rapid 
means of screening for the mutation by restriction enzyme digestion in the final product.
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To generate mutations, the linear pUL98CAT was used as a template. See appendix m  
for specific primer sequences used for the generation of each substitution mutation. One- 
tenth volume of the mutated PCR product was digested with Hindlll or HindHH and 
EcoRl for confirmation of the EcoRl insertion. The remaining purified fragment was 
religated at the HindlU site -309 in the UL98 promoter and tested in transient transfection 
assays.
Sequencing of plasmid DNAs
Sequencing of the UL98 promoter was performed by the ALF DNA Sequencer 
utilizing the autoread kit (Pharmacia Biotech) and fluourescein-dNTP (F-dNTP) labeled 
primer/ quick annealing method. The sequencer is designed for the automated 
electrophoresis and analysis of sequencing reactions by the direct detection of 
fluorescently labeled DNA molecules. This differs from the traditional Sanger dideoxy 
sequencing method by the use of a fluorescently labeled primer or fluorescienated dNTPs 
instead of radioactive deoxynucleotides.
Electrophoresis is carried out in a vertical gel cassette. During electrophoresis, 
the fluorescently labeled fragments in each lane migrate downwards through the gel. The 
fixed laser beam passes through the glass light coupler located between the notched glass 
plate and the thermoplate of the gel cassette. The beam excites the fluorescently labeled 
DNA band and the light emitted is detected by photodetectors located behind the gel.
The photodetector signals are collected, digitized and sent to the computer for storage and 
processing.
For each plasmid to be sequenced, 5 micrograms (pg) of closed circular DNA was 
mixed with 25 picomoles (pmol) of the fluorescein-dNTP labeled primer in a final
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volume of 30 pi. 1.5 pi of IN NaOH was added and incubated at 65°C for 5 minutes 
(min). Tubes were transferred to 37°C and IN HC1 was added along with 2 pi of 
annealing buffer. Tubes were then incubated at 37°C for 10 min. After a quick spin, the 
tubes were placed at room temperature for 5 min. F-dNTP labeling mix and T7 DNA pol 
was added and incubated at 37°C for 5 min. Following the addition of extension buffer 
and DMSO, 5 .4 pi of the mixture was added into 3 pi of A,C,G, T mixes and incubated at 
37°C for 5 min. The reactions were stopped by the addition of 6 pi of stop solution and 
placed on ice. Before loading the samples onto the electrophoresis gel, the samples were 
heated for 5 minutes at approximately 90°C. Previously, the sequence of the UL98 
promoter region and the initiation site was published for both AD 169 (1) and Towne 
(185) strains of HCMV.
Transient transfection and superinfection assays 
In transient expression experiments, pUL98CAT or its mutated derivatives were 
assessed by transient cotransfection with plasmids expressing one or both of the MIE 
proteins as previously described (38, 189) or by superinfection with the Towne strain of 
HCMV. Ceils were seeded at IxlO6 cells per 100mm dish (or 3.5 x 10s cells per 60 mM 
dish) on day one as determined by hemocytometer counts. On day two, using DEAE 
dextran method (191), cultures of HFF 1 cells (at 80-90% confluency) on 100 mm dishes 
(or 60 mm dishes) were transfected with 5 (or 2) pg of indicated reporter plasmid DNA. 
Cells were cotransfected with 5 (or 2) pg of MIE gene plasmids (IE1 and IE2), followed 
by the addition of 1 ml of sterile Tris buffered saline (30 mM Tris-HCl pH 7.5, 150 mM 
NaCl) (TBS) and 0 5 mg of DEAE-Dextran (Pharmacia, Uppsala, Sweden). The DNA 
solution was added to cells washed prior with TBS and then incubated at 37°C for 30
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minutes (rocking every 10 minutes). 10 ml of lOOmM chloroquine (Sigma, St. Louis, 
MO) was added and the cells were incubated at 37°C for 3 hours. At 3 hours, media was 
removed and cells were then given fresh media and incubated at 37°C. Cells were then 
harvested 48 hours after transfection. For maximal transfection efficiency, a total of 10 
|ig of plasmid DNA was added per 100 mM dish initially seeded with 106 cells (38, 111). 
When activated by the Towne strain of HCMV, transfected cells were infected at 18-24 
hours post transfection with 10-20 PFU per cell of HCMV and incubated for 2 hours.
The inoculum was removed from cells and fresh media overlaid. Cells were harvested at 
24, 48, or 72 hours post infection and extracts were processed.
Chloramphenicol acetyl transferase (CAT) assay 
CAT activity was determined as previously described (38). 1 ml of TBS was 
added to transfected cells which were then scraped into microfuge tubes, spun down via 
centrifugation, and resuspended in 100 ul of 0.25M Tris pH 7.8. Cells then underwent 
three rounds of freeze-thaw followed by centrifugation to remove cell debris. The 
supernatants were transferred to new microfuge tubes, and heat inactivated at 68°C for 10 
minutes. 20 p.1 of heat inactivated CAT extract were used per CAT assay reaction. A 
reaction mix also contained 0.1 uCi of 14C-chloramphenicol (Amersham, Chicago, IL), 
70ul of 0.25M Tris pH 7.8, 34 ul of sterile deionized water, and 20 ul of acetyl CoA 
(4mM). The reaction was incubated at 37°C for 30 minutes. 750 ul of ethyl acetate were 
added to stop the reaction followed by vortexing and centrifugation of each sample for 1 
minute. The top aqueous phase was transferred to a new microfuge tube and dried down. 
The dried product was resuspended in 20 ul of ethyl acetate.
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To determine the percent acetylation by chloramphenicol acetyltransferase 
(CAT), extracts were spotted onto thin layer chromatography (TLC) plates followed by 
autoradiography at -80°C for 16 -24 hours. The actual percent acetylation was obtained 
by applying TLC plates to phosphorimager (Molecular Dynamics) analysis.
In the experiments described above, CAT protein was not determined. However, 
pg quantities of protein could be determined in the Bradford Coomassie brilliant blue 
assay, which is accomplished by measurement of absorbance at S90 nm. This 
absorbance is compared to the absorbance of different amounts of a standard protein such 
as BSA (9).
Preparation of Nuclear Extracts
Human foreskin fibroblasts were infected with HCMV at 20 PFU/cell at 
confluence. After 1 hour adsorbtion, media containing virus was aspirated and cells were 
overlaid with fresh growth media. Extracts were prepared by a modification of the 
Dignam procedure (39). Cells were first washed with Tris-buffered saline (TBS) and 
harvested at a density of 5 x 106 cells per ml by scraping into buffer A containing 0.5% 
NP-40 and protease inhibitors [aprotinin 2pg/ml, leupeptin 0.5 pg/ml, pepstatin lpg/ml, 
and phenylmethylsulfonyl fluoride (PMSF) ImM]. Cells were lysed on ice by gentle 
pipetting for 10 minutes, and the nuclei removed by centrifugation at 1,500 x g. Nuclei 
were resuspended at approximately 1.5 x 107 nuclei per ml in buffer C containing 
protease inhibitors and incubated on ice with occasional gentle pipetting (every 10- 
minutes) for 30 min. Extracts were centrifuged at 50,000 x g, supernatant was removed, 
dialyzed against buffer D (1M Hepes pH 7.9, IM KC1, 0.5M EDTA, 10% NP40,100% 
glycerol, ImM DTT, and PMSF) (This is a dialysis buffer containing KC1 used to
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normalize salt concentration during nuclear extraction, and the same buffer solution is 
also used for the preparation of nuclear extracts for both resuspension and dilution), and 
stored at -80°C.
CREB Protein
CREB protein (cat #: sc-4002) replaced the HCMV infected cell nuclear extracts 
and was incubated with the UL98 36 bp CRE specific radiolabeled probe in gel mobility 
shift assays. The CREB protein was purchased from Santa Cruz Biotechnology, Inc. 
CREB-1 bZIP (amino acids 254-327) was expressed in E. coli as a 10-14 kDa 
polypeptide mapping within the DNA binding and dimerization domain of CREB. The 
protein product was purified from bacterial lysates, and supplied as 50 pg purified protein 
in 0.1 ml PBS ( I pg/2 pi). The protein was assayed in a 1.100 protein dilution with 
Buffer D.
Gel mobility shift analysis
5-10 pg of nuclear extracts (10 pi) were incubated with 5 pg of poly (dl-dC) poly 
(dl-dC) (5 pi) and fold excess competitor DNAs for 15 minutes at room temperature in 
50% buffer D. Radiolabeled probe was added (40,000 to 50,000 cpm, 0.5 to lng of 
DNA), and the incubation continued for 30 minutes. Samples were subjected to 
polyacrylamide gel electrophoresis in one or one-half X Tris-borate-EDTA (TBE). Gels 
were dried and subjected to autoradiography (10).
Radiolabeling of DNA fragments or double-stranded synthetic oligonucleotides
DNA fragment
A 143 bp or 239 bp DNA fragment from the UL98 promoter region was isolated 
by restriction enzyme digestion using Niarl and Mscl or Marl and Aval respectively, and
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end-labeled with [y-32P]-ATP and T4 polynucleotide kinase and purified with Ix STE 
buffer on a Nuctrap push column.
The 143 bp UL98 probe from -194 to -51 was isolated after restriction enzyme 
digestion of pUL98C AT with Narl and Mscl and polyacrylamide gel electrophoresis.
The 148 bp nonspecific competitor fragment, lacking any UL98 specific sequences, was 
isolated in a like manner from the plasmid pSVOCATd.
Double-stranded oligonucleotides 
Complementary single stranded oligonucleotides (10 pg each) were incubated at 
70°C for 30 minutes in an annealing reaction in 20mM Tris-HCl (pH7.5)-50mM NaCl- 
lOmM MgCh and the reaction mixture was subsequently allowed to cool to room 
temperature. The annealed product was then 5’ radiolabeled with [y-32P]-ATP and T4 
polynucleotide kinase and purified by nondenaturing polyacrylamide gel electrophoresis. 
For each radiolabeled DNA reaction, 1 pi was counted for cpms to determine amount to 
use per reaction in gel shift mobility analysis.
CRE- 36mer 5CCATGCTGCACGAATACGTCAGAAAGAACGTGGAG3’ and 
3 GGTACG ACGTGCTT ATGC AGTCTTTCTTGC ACCTC5 ’
TCF-1- 29mer 5 ’ AAAGAACGTGGAGCGTCTGTTGGCCACTAT3 ’ and 
3 TTTCTTGCACCTCGCAGACAACCGGTGATA5 ’
CREm- 36mer 5 ’ CC ATGCTGC ACG AAG AATT C AG AAAGAACGTGGAG3 ’ 
3,GGTACGACGTGCTTCTTAAGTCTTTCTTGCACCTC5’
TCFm- 29mer 5’ AAAGAACGTGGAGCGGAATTCGGCCACGAG3 ’ and 
3 TTTCTTGCACCTCGCCTTAAGCCGGTGCTC5’
SIE/yIRE- 30mer 5 ’ GGCC ACG AGCG ACGGGCT GT ATTT AT AT AA3 ’ and
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3 ’CCGGTGCTCGCTGCCCGAC AT AAAT AT ATT 5 ’
Sm- 30mer 5 GGCCACGAGCGAATTCCTGTATTTATATAA3 ’ and 
3 ’ CCGGT GCT CGCTT AAGG AC AT AAAT AT ATT 5 ’
Im- 50mer
5’CCACGAGCGACGGGGAATTCTTATATAACGCCTTTCGGCGCACCACCAGC3’
and
3 GGTGCTCGCTGCCCCTTAAGAATAT ATTGCGGAAAGCCGCGTGGTGGTCG5 ’ 
Smlm- 37mer 5 ’CC ACGAGCGGAATTCGAATTCTT AT AT AACGCCTTTCG3 ’ and 
3 ’GGTGCTCGCCTTAAGCTT AAGAATAT ATTGCGGAAAGC5’ 
USI3m- 35mer 5 GCGTCTGTTGGGAATTCGCGAATTCGAATTCTTAT3’ and 
3 ’CGC AGAC AACCCTT AAGCGCTT AAGCTTAAGAAT A5 ’
To determine the HCMV infected cell protein(s) that bind specifically to 
elements within the UL98 promoter, the protein-DNA complexes formed in 
standard gel mobility shift analysis were assessed for further retardation by the 
addition of antibody(s) specific for proteins which are thought to bind the UL98 
promoter elements. 5-10 pg of nuclear extracts (10 pi) were incubated with 5 pg 
of poly (dl)-poly (dC) (2 pi) for 15 minutes at room temperature in 50% buffer 
D. A 32P radiolabeled probe of a specific promoter element was added and 
incubation continued for 30 minutes. Antibodies used include a CREB-1 mouse 
monoclonal (24H4B / corresponding to amino acids 254-327) which is non- 
crossreactive with other ATF/CREB transcription factors; ATF-1 mouse 
monoclonal (25C10G/ epitope corresponding to amino acids 39-271) which
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reacts with ATF-1 p35, CREB-1 p43 and CREM-1 of mouse, rat and human 
origin; or ATF-2 mouse monoclonal (F2BR-1 / corresponding to amino acids 
350-505) which is noncrossreactive with other ATF/CREB transcription factors. 
All antibodies listed above were commercially supplied by Santa Cruz 
Biotechnology, Inc. IRF-3 (rabbit polyclonal), generated in rabbits against IRF- 
3 amino acids 107-208 fused to glutathione S transferase (GST), was a gift from 
the laboratory of Michael David, Ph.D., UCSD, San Diego, Ca. For each 
antibody, 1 ul (or 2 ug) was added for an additional 30 minutes.
Cloning Methodology 
Enzymes
Restriction endonucleases were obtained from New England Biolabs (NEB) 
(Beverly, MA ), Promega, (Madison, WI ), and Gibco BRL (Baltimore, MD). All 
enzymes were used according to instructions recommended by the manufacturer or as 
described in Maniatis (111). The Klenow polymerase fragment and the calf intestinal 
alkaline phosphotase (CIP) were ordered from Boehringer Mannheim Biochemicals, 
Indianapolis, In. T4 polynucleotide kinase was ordered from Pharmacia. T4 DNA 
ligase was ordered from New England Biolabs. Taq polymerase was ordered from Gibco 
BRL
Restriction Endonuclease Digestion 
Plasmid DNA construction was performed by methods previously described 
(111). Digestions were carried out in reaction mixes that contain 20 mM tris, pH 7.5, 10 
mM MgCh, 1 mM DTT, and the appropriate NaCl or KC1 concentrations or in some 
instances, buffer supplied with the restriction endonucleases. One to five units of
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restriction endonuclease per pg of DNA were used in each reaction. In the case of 
vectors requiring dephosphorylation of S' ends, 20 units of high concentration calf 
intestine alkaline phosphatase (CIP) were added to the reactions. DNA fragments were 
then separated and purified by polyacrylamide gel electrophoresis. One fifth volume of 
loading dye (50% glycerol, 0.1 % bromophenol blue (BPB) 100 mM EDTA, pH 8.0) was 
added to the reaction prior to loading onto gel.
To separate and isolate products of restriction endonuclease digestion, reactions 
were loaded onto a 5% or 10% polyacrylamide gel run in Ix tris-borate-EDTA (TBE) 
buffer. Upon the completion of electrophoresis, the gel was stained with ethidium 
bromide (EtBr), visualized on a UV light box, and bands of interest were excised from 
the gel. To remove the DNA from the excised gel slice, electroelution was performed in 
l/20x TBE buffer. Finally, DNA was ethanol precipitated in the presence of 200 mM 
NaCl and 100% ethanol at -80°C for 20 minutes. The precipitate was pelleted by 
centrifugation in a 4°C microfuge for 15 minutes. The pellet was washed in 70% ethanol 
and recentrifuged at 4°C for 5 minutes. Ethanol was discarded and the pellet was dried 
by vacuum and resuspended in an appropriate volume of sdHiO.
Repair Ends of DNA Fragments 
The pSVOCATd reporter-CAT construct contains a unique HindUI site just 
upstream of the CAT gene. To insert the wildtype or mutant UL98 promoter fragment, 
the ends of the DNA fragment were filled-in in a reaction that included dNTP, Tris pH 
7.0, MgCk, 1M DTT, 1-2 ul of Klenow polymerase. The reaction was incubated at room 
temperature for 30 minutes.
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Ligation of Linkers onto DNA Fragments 
Linkers were first phosphorylated as described in Maniatis (111), phosphorylated 
linker reaction contained 5mM ATP, T4 polynucleotide kinase (PNK), T4 PNK buffer, 
and incubated at 37 °C for 30 minutes. Linker ligations were performed using 50-100 
molar excess of linkers to DNA fragments. The total DNA concentration was 10-20 
|ig/|il in lx ligation buffer, and T4 DNA ligase. The reaction was carried out at 16°C for 
16 -24 hours.
Ligation of DNA fragments with Vector DNA 
Ligation reactions were performed essentially as described in Maniatis (111).
DNA fragments were incubated with linear plasmid vector (pSVOCATd) DNA (1:1 to 
4:1 ratio of insert to vector, 10-20 pg/|il DNA total) in lx ligation buffer, 5 mM ATP, 
and T4DNA ligase for 16-24 hours. Following incubation, plasmid DNA was introduced 
into bacteria.
Amplification and Purification of plasmid DNAs 
Competent cells used for transformation (HB101 or XL1 BLU) were prepared as 
described in Maniatis (111). Overnight small cultures of bacteria in Luria-Bertani (LB) 
media were subcultured into 250 ml LB media and grown to an absorbance of 0.4 to 1.5 at 
550 nm. Cells were chilled quickly to 4°C, pelleted, and resuspended in 100 mM CaCb- 
Following a 30 minute incubation at 0°C, cells were pelleted in 100 mM CaCh 
containing 15% glycerol, aliquoted into prechilled microfuge tubes and refrigerated on
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ice at 4°C overnight. Bacteria were then quick frozen in 250 pi aliquots in a dry ice/ 
ethanol bath and stored at -80°C.
For transformation reactions, 20 til ligation reaction mix was incubated with 100 
pi of competent cells for 30 minutes on ice. (4°C). The bacteria and ligation/competent 
cell mix was then incubated at 42°C for 2 and one-half minutes followed by 15 minutes 
incubation on the bench top at room temperature. The reaction mix was placed in 1 ml of 
LB media and placed in a shaking incubator for 1 to 1.5 hours. 100-200 pi of bacteria 
were plated onto an LB/agar plate containing 100 mg/ml ampicillin and incubated at 
37°C overnight.
Screening of plasmid DNA 
To screen for the desired plasmid, bacterial colonies were picked and placed in 
2.0 ml cultures of LB media containing 50 ug/ml ampicillin and grown at 37°C for 16-24 
hours. Plasmid DNA was isolated by a modified alkaline lysis method. 1.5 ml of each 
culture were pelleted, media removed and discarded, and bacteria suspended in 100 pi of 
solution I [25 mM Tris-Cl, 8% sucose, lOmM EDTA, and lysozyme (5 mg/ml)]. 
Following a 5 minute incubation at room temperature (25°C), 200 pi of solution II (0.2N 
NaOH, 1% SDS) was added. Samples were mixed by inversion and incubated on ice for 
5 minutes. 150 pi of solution III [3M Potassium Acetate (KAc), 11.5% glacial acetic 
acid] was added, mixed by inversion and placed on ice for an additional 5 minutes. 
Cellular debris and chromosomal DNA was pelleted. Plasmid DNA within supernatant 
was precipitated in 1 volume of 100% ethanol, dried and resuspended in sterile deionized 
water (sdlfcO). Plasmid DNA was sufficient for restriction enzyme analysis. RNAse 
was added to each sample and incubated at room temperature to remove any RNA
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present. To screen plasmid DNA, restriction endonuclease digestions were performed as 
previously described. Reaction mixtures were stopped with loading buffer [0.25% 
bromphenol blue (BPB), 0.25% xylene cyanol, and 30% glycerol). Each was loaded onto 
a 1.0 to 1.5% agarose gel or a 5% acrylamide (short/thin) gel to resolve fragments smaller 
that 500 bps.
Large Scale Plasmid Preparation 
To isolate large scale plasmid DNA, bacteria containing desired plasmid were 
grown until mid to late log phase (OD600 nm of 0.6 to 0.8) in 250 ml of LB media in the 
presence of ampicillin. Plasmid DNA was amplified with 1.7 mg of chloramphenicol per 
ml of culture. Bacteria was pelleted and plasmid DNA was purified by SDS-high salt 
extraction method. Bacteria pellets were resuspended in 7.5 ml 25% sucrose solution 
[10% (12.5 grams) sucrose, 50mM (10 ml) Tris-Cl] and 1.5 ml of 10 mg/ml lysozyme. 
After incubation on ice 5 minutes, 3 ml of 0.25 M EDTA was added. Following a second 
5 minute incubation on ice, the mixture was wanned to room temperature and 1 ml of 
12.5% SDS was added. The sample was mixed by inversion and incubated at room 
temperature for 15 minutes. After chilling samples to 0°C, 2.5 ml 5M NaCl was added 
and the mixture was incubated for 30 minutes. Samples were centrifuged at 19,000 rpm 
in a Sorvall ss34 rotor at 4°C for 45 minutes. The supernatants were transferred to a fresh 
tube, the volume elevated to 20 ml with dsf^O, and treated with 100 pi of 10 ng/ml 
RNAase A at 37°C for 1 hour. Following phenol-chloroform extraction, DNA was 
precipitated, pelleted, dried via vacuum, resuspended, and finally purified twice through 
cesium chloride gradients (190, 192, 193, 195, 201) to remove bacteria, genomic DNA,
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and RNA. Each plasmid DNA was sufficiently pure for transfection into eukaryotic 
cells.
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CHAPTER IV 
RESULTS
Identification of the UL98 promoter relative to the putative TATA box and the CAP 
site at +1: cloning and characterization of the UL98 promoter in a CAT-reporter
construct
The gene product of UL98 was previously identified as a 58 kDa protein 
homologous to the herpes simplex virus (HSV) alkaline exonuclease (1). Sequence 
analysis revealed direct and inverted repeats greater than or equal to 8 bp located 
upstream of the UL98 open reading frame (ORF). Consensus binding sites for 
ATF/CREB (-82), E2F (-127), and SRF (-152) were also found relative to the CAP site.
A putative TATA box motif was present at -28. With the information gathered thus far, it 
was feasible to search for and isolate the promoter within this region. The plasmid 
pCBX8.1 contains an 8.1 kb BamHl to Xbal fragment from Xbal-C containing the pp28 
gene region. Initially, a 601 bp fragment containing the UL98 promoter region was 
removed by restriction enzyme digestion with Pstl and Xhol. This fragment included 
sequences from the UL97 ORF as well as the putative ATG of UL98. Therefore, it was 
necessary to digest the fragment further to include only the putative UL98 promoter. By 
digestion of the 0.6 kb fragment with the restriction enzyme BsrFl, a 421 bp fragment 
from -309 to +112 (Figure 1) was isolated. The promoter fragment ends were filled-in 
with dNTPs by Klenow polymerase to blunt the ends and Hindlll linkers were added.
The UL98 promoter fragment was cloned into the pS VOCAT reporter construct at a 
unique HindlH. site 5’ to the chloramphenicol acetyltransferase (CAT) gene and 
designated pUL98CAT (Figure 2). Automated sequencing confirmed the proper
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-309 CCGGCGCGGC CTGCCGCGCG TTGGAGAACG GTAAGCTC’AC GCACTGCTCC GACGCCTGTC TGCTCATTCT GGCGGCGCAA ATGAGCTACG 
-219 GCGCCTGTCT CCTGGGCGAG CATGGCGCCG CGCTGGTGTC GCACACGCTG CGCTTTGTGG AGGCCAAOAT GTCCTCGTGT CGCGTACGCG
-129 CCTTTCGCCG CTTCTACCAC GAATGCTCGC AGACCATGCI' GCA CGAA IAg-jnEA GAA AGA ACGTGGAGCG TCIQITGGCC ACGAGi
-39 GG rTOTATIT ATAIAACGCC THX-GGCtJCA CCACCAGCAT AATCTtiCGAG GAGGACC1TG ACGGTGACTG CCtiCCAACTO TTCCCCGAGT+(
+51 AACCGGGACG CGGAACGTGA CGGTTGCTGA GGtiGAAAGGC AACAGAGAAG GTACAAACCC A
FIG. 1. Sequence of the putative UL98 promoter. The UL98 promoter was isolated by digestion with BsrFl. A 421 
base pair fragment from -309 to +112 was isolated and HindIII linkers were added to the ends. The elements specific 
for cellular transcription factors are underlined and represented by boxed abbreviations. The TATA box at -28 and 
the CAP site at +1 are indicated.
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FIG. 2. Generation of the pUL98C AT construct. The promoter region of 
UL98 was obtained by digestion of the UL98 genomic construct with the 
restriction enzyme BsrFl. The promoter fragment was isolated, Hindlll 
linkers added to the ends, and cloned into the unique Hindlll site of 
pSVOCATd upstream of the chloramphenicol acetyltransferase (CAT) 
gene to generate pUL98C AT.
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FIG. 3. Activation of early promoters ppolCAT and pUL98CAT by IE1 (IE72) and IE2 
(IE86) gene products. Human foreskin fibroblast cells were transfected with S pg of either 
reporter plasmid and 5 pg of the plasmid expressing IE1 and 1E2 (pSVH) or 5 pg of the 
plasmid without IE1 and IE2 (pSVOD). Cells were harvested at 48 hours and assayed for the 
expression of CAT.
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insertion and orientation.
The activation and subsequent regulation of early promoters require viral as well 
as cellular transcriptional factors. In transient transfection assays, HCMV promoters with 
early kinetics are activated by immediate early (IE) proteins (38, 181, 186,189). To test 
the UL98 promoter for activation capability in the presence of HCMV IE proteins, 
pUL98CAT was cotransfected with a plasmid (pSVH) that expresses LEI/ IE72 (UL123) 
and TE21IE86 (UL122) into human foreskin fibroblast (HFFI) cells. An expression 
plasmid lacking the IE specific sequences (pSVOD) served as a negative control and was 
also cotransfected with pUL98C AT. The cells were harvested at 48 hours, processed, 
and assayed for CAT activity. The HCMV polymerase promoter is a well characterized 
early promoter strongly responsive to IE proteins in transient assays. pUL98CAT 
responsiveness to IE transactivators resembled the CAT activity observed from the 
polymerase promoter construct ppolCAT (Figure 3). The pSVOD plasmid, lacking IE1 
and IE2 gene regions was unable to activate the promoter. Therefore, pUL98CAT 
responded well to IE proteins in transfection experiments and UL98 promoter sequences 
are activated.
Previous studies have documented that early gene activation requires the presence 
of immediate early (IE) transactivators (22, 38, 184, 189). Two such activators, IE72 and 
IE86 proteins, are necessary for the activation of various early promoters (pol, pp65, 2.2 
kb RNA) in transient transfection assays. While several early promoters utilize both IE72 
and IE86 for activation (UL54, UL83 promoters), others may only require IE86 for 
activation (UL112-113, UL4 promoters). The initial goal was to test the IE requirement 
for the activation of the UL98 promoter. pUL98CAT was cotransfected with pSVH (EE1
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FIG. 4. Activation of pUL98CAT by IE1 and/or IE2. The ability of cDNAs 1EI and/or IE2 
to stimulate the UL98 promoter was compared to the genomic construct (pSVH). pUL98CAT 
(5 pg) was cotransfected with pIE72kD (5 pg), pIE86kD (5 pg), both pIE72kD and pIE86kD 
(2.5 pg of each), or pSVH (5 pg). Cell were harvested at 48 hours post transfection and 
assayed for CAT activity. Experiments were carried out in duplicate.
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and IE2 administered in a single plasmid), pIE72KD (IE I only), pIE86KD (IE2 only), or 
pIE72KD/ pIE86KD (IE1 and IE2 administered in separate plasmids). The cells were 
harvested and assayed for CAT activity as described above. Figure 4 shows that 
activation of the UL98 promoter requires IE1 and IE2 administered in a single plasmid 
(pSVH) for the most efficient activation. pIE72KD/86KD administered separately 
worked less well. The plasmid pIE86KD is able to activate the UL98 promoter (Figure 
4), but to a lesser extent than with the cooperation of both IE proteins. pIE72KD alone 
scarcely activated the UL98 promoter. Therefore, IE72 and EE86 viral proteins together 
are required to efficiently activate the UL98 promoter. These data supports the IE 
transactivator model for the expression of early and late genes (186).
Deletion analysis of the UL98 promoter
The UL98 promoter contains consensus binding sites for ATF/CREB (cyclic AMP 
response element binding protein), E2F, and SRF (serum response factor) (223). Each of 
the proteins mentioned above plays an important role in the process of transcriptional 
activation. CREB is a cyclic AMP-regulated transcription factor defined as a sequence 
specific DNA activity (104). This protein binds to the cyclic-AMP response element 
(CRE) within promoters of cAMP inducible genes and mediates their induction in 
response to activation of the protein kinase A (PKA) pathway (63, 104). Several HCMV 
early genes utilize ATF/CREB sites for transcriptional activation. E2F is a cell cycle 
factor that binds to the product of the retinoblastoma gene, cyclin A, and adenovirus E4 
(123). It can be induced by E1A and serum and functions in cell cycle regulation (123).
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FIG. 5. Removal of the 3’ Hindlll site to generate pdH309CAT. pUL98CAT was partialled with Hindlll. The 
linear products were isolated by acrylamide gel electrophoresis (5%). The purified product was religated followed 
by digestion with HindlU and Aval to screen for the DNA product containing the disrupted 3’ Hindlll site. The 
altered promoter construct was then used for the generation of deletion mutations within pUL98CAT.
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The serum response factor (SRF) is a 67 kDa protein (78). Binding to the SRE is 
essential for response to serum stimulation. SRE activity can be modulated by 
intracellular cAMP levels (168). In addition, a DNAsis sequence database search showed 
that elements for a putative TCF-1 (T-cell specific factor) (-59), an SIF (sis-inducible 
factor) (-43), and a gamma interferon (-37) are present as well.
The T-cell factor (TCF-1), part of the high mobility group (HMG) protein family, 
is a DNA binding protein functional in DNA bending (205, 206, 212). Found specifically 
in T-cells, closely related transcriptional regulators can be found in other cell types. 
Extensively characterized in the c-fos promoter, the sis-(PDGF) inducible factor (SIF), 
mediates induction by platelet derived growth factor (PDGF) (159, 160). In response to 
interferon a/(3 stimulation, SIF components (signal transducers and activators of 
transcription) bind the SIE (159, 160). Lastly, the interferon (IFN) gamma stimulates 
factors functional in the transcription of genes that function in the immune response. 
Several binding sites accommodate interferon gamma activated factors (34. 35). To 
determine the importance of each response element in UL98 promoter activation, it was 
necessary to generate deletions in a stepwise manner from the promoter’s 5’ end at 
-309 to the TATA box at -28.
Initially, the pUL98CAT construct required the inactivation of its 3’ HindUl site 
at +112. In this way, deletions could be generated by digesting with the 5’ Hindlll site at 
-309 and 1) utilizing the unique downstream sites present or 2) inserting a 3’ Hindlll site 
at desired positions. The inactivation of the 3’ HindUl site at +112 in the wild-type 
pUL98C AT construct was generated by partial digestion with HindUl. The linear
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FIG. 6. Construction of UL98 deletion mutants utilizing pdH309CAT. The altered 
UL98 promoter construct was digested with Hindlll and a second restriction enzyme 
site downstream to generated deletions from the 5’ end of the promoter. The deleted 
site for each construct was discarded. The remaining sequence was isolated by 
acrylamide gel electrophoresis (5%), filled in with klenow, and religated with T4 
DNA ligase. Variant promoter constructs include pl94CAT [Hindlll (-309) to Marl 
(-194)], pl36CAT [Hindlll (-309) to Sunl (-136)], and p51CAT [Hindlll (-309) to 
Mscl (-51)].
+112
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FIG. 7. A schematic representation of site-directed mutagenesis by 
overlapping PCR. The two solid lines represent the wildtype double stranded 
UL98 promoter. Four synthetic oligonucleotides (primers) are generated: two 
internal primers that contain the substitution mutation (grey box) and two 
external primers used to amplify each strand. In two separate reactions, a pair 
of primers (a+b or c+d) is incubated with the wildtype promoter (pUL98CAT) 
to generate two PCR products, which overlap at the mutation. To generate the 
mutated strands, oligos a and b were incubated with UL98 ppDNA as template 
to produce the 5’ portion of the promoter with the mutation in the first reaction 
(1). Oligos c and d were treated in the same manner in a sepatate reaction to 
generate the 3’ portion of the mutated promoter. The products of reaction one 
were subjected to klenow to remove additional A’s attached by Taq 
polymerase. The products were then used as template in a second reaction (2) 
with only the external primers present to amplify the final full-length 
fusion/mutant product. All PCR reactions were carried out under the same 
conditions in a thermocycler (Cetus). PCR conditions were set at 94°C, 72°C, 
and 55°C for 32 cycles. For deletion mutations a Hindlll site was generated, 
and for substitution mutations an EcoRI site was generated.
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HindUl products were purified through a 5% acrylamide gel and religated. The products 
were then screened by restriction enzyme digestion with Aval and HindUl. Positive 
constructs for the inactivated 3’ Hind HI sequence lost the ability to generate a 62 bp 
Aval to HindUl fragment and were called pdH309CAT (Figure 5). To determine whether 
the altered 3’ HindUl site affected the promoter activity, the pdH309CAT construct was 
tested in comparison to the parent pUL98CAT construct for responsiveness to IE 
proteins. In transient transfection assays, pUL98CAT or pdH309CAT was cotransfected 
with pSVH in HFF 1 cells, and at 48 hours assayed for CAT activity. The results showed 
that CAT activity in cells transfected with pdH309CAT resembled that of pUL98CAT, 
indicating that the inactivation of the 3’ Hind in site did not negatively impact promoter 
activation by IE proteins (see Figure 10).
The pdH309C AT construct could now be used to generate a series of deletion 
mutations by progressively removing transcription factor binding sites 5’ to 3’. Three 
deletion mutants were initially generated (Figure 6). pdH309CAT was digested with 
Hindlll (-309) and a unique downstream restriction enzyme site to produce constructs 
that were deleted to -194 (HindUl to Narl), -136 (HindUl to SmwI), and -51 (HindUl to 
Mscl) in the UL98 promoter. HindUl linkers were added to the ends and the linear 
fragments were purified through a 5% acrylamide gel and isolated by electroelution.
Each of the three fragments was religated at the deleted site to generate p-194CAT, 
P-136CAT, and p-51CAT. The constructs were subsequently tested in transient 
transfection assays.
Unique restriction enzyme sites within the UL98 promoter are randomly 
positioned, not conveniently separating each transcription factor-binding site. Therefore,
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an overlapping PCR mutagenesis approach (Figure 7) was employed to strategically 
insert HindUl sites at desired positions between the response elements. Three elements 
between -136 and -51 [ E2F at -127, the cyclic AMP response element (CRE) at -82, and 
the putative T-cell specific factor (TCF) element at -59], and two elements [the sis- 
inducible element (SIE) at -43 and the gamma interferon response element (ylRE) at -37] 
between -51 and -28 required separation. Therefore, it was necessary to utilize a method 
for the insertion of restriction enzyme sites. The pdH309CAT construct contains a single 
5’ Hindlll site at -309. By the insertion of a second HindUl sequence at a downstream 
site, subsequent digestion with Hindlll would result in the removal of other transcription 
factor binding sites.
Briefly, to generate each new Hindlll site, four synthetic oligonucleotides (oligos) 
were generated and used as primers for the Hindlll insertion in two separate reactions 
(Figure 7). Two internal primers (b,c) contained the Hindlll site to be substituted, and 
the two external primers (a,d) consisted of vector sequences necessary to amplify the 
altered promoter. In the first reaction, complementary primers [(a and b) or (c and d)] 
were paired (one external and one internal) to insert and amplify the restriction enzyme 
sites into the sense and antisense DNA strands separately. In a second reaction, two 
overlapping products were then incubated with the two external 5’ (a) and 3’ (d) primers 
to amplify a double stranded UL98 promoter product with a Hindlll site inserted (Figure 
7). While new internal primers were generated for each HindUl insertion, the same 
external primers (a and d) could be used. The final PCR product was digested with 
HindUl and thereby deleted to -85, -64, -34, or -28. For each deletion, the larger HindUl 
fragment in tandem with the CAT-reporter construct was purified by electrophoresis
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FIG. 8. Insertion of the Hindlll site for the construction of deletions in the 
UL98 promoter. pdFI309CAT acts as a template for the two reaction process 
of overlapping PCR mutagenesis. Reaction one utilizes four primers (two 
internal and two external) for the insertion of the Hindlll sequence. Reaction 
two requires the use of two external primers for the amplification of the 
mutated product. Final PCR products are purified through a 5% acrylamide 
gel and inserted into the unique Hindlll site of pSVOCAT. Deleted promoter 
constructs are as follows: p85CAT (-85), p64CAT (-64), p34CAT (-34), and 
p28CAT (-28).
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through a 10% polyacrylamide gel and religated (Figure 8).
The importance of each element could be assessed because each promoter 
construct now contains one less transcription factor binding site with each deletion 
toward the TATA box. Each construct was then evaluated in the presence of IE 
regulatory proteins to determine the impact of each transcription factor binding site on 
UL98 promoter activation. In transient transfections, each deletion construct p-194CAT, 
P-136CAT, p-85CAT, p-64CAT, p-5lCAT, p-34CAT, and p-28CAT (Figure 9) was 
cotransfected in the presence of IE proteins with pSVH, harvested 48 hours after and 
processed for determination of CAT activity.
Results in Figure 10 show that while promoter constructs deleted to -194, -136, - 
85, and -64 were activated to levels similar to wildtype, the promoter deleted to -51 was 
drastically reduced in promoter activity. Promoter constructs deleted to -34 and -28 (p- 
34CAT and p-28CAT) were also activated at or slightly below wildtype levels, p-51CAT 
was the only deletion construct able to abrogate UL98 promoter activity. From these 
data, sequences within a 13 bp (-64 to -51) region were found critical for the activation of 
the UL98 promoter (Figure 10).
The T-cell factor (TCF) element (5’-TCTGTTGG-3’) is positioned from -59 to - 
54 on the negative strand (3’-CCAACAGA-5’) and may therefore serve as a critical 
component in the regulation of the UL98 promoter. It was anticipated that the removal of 
all transcription factor-binding sites 5’ of the TATA box would significantly reduce 
promoter activity as found with other early promoters. It was surprising to observe that, 
in transient assays, deletions downstream of -51 but upstream of the TATA box resulted 
in promoter activity similar to wildtype (See Figure 10). This observation suggests the
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FIG. 9. UL98 promoter deletion mutants. The elements specific for cellular transcription factors are 
underlined and represented by boxed abbreviations. Each deletion removes a cis-element from -309 
toward the TATA box at -28. Deletions were generated by restriction enzyme digestion or overlapping 
PCR mutagenesis and confirmed by automated sequencing. Variant promoter constructs are named to 
the right of each illustrated construct.
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DELETIONS
FIG. 10. Responsiveness of promoter deletion mutants to IE proteins. 
Individual promoter construct DNAs (5 pg) were cotransfected with 5 pg of 
pSVH into human fibroblasts, harvested at 48 hours, and assayed for CAT 
activity. Results were converted to fold activation compared to wildtype as 100 
percent. This data shows that the region important for promoter activity lies 
between -64 and -51.
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FIG. 11. UL98 promoter deletion mutants activated by HCMV infection. Activation of the 
UL98 parental and variant promoters were assessed by transfection of each plasmid (10 pg) into 
human fibroblast cells followed by superinfection with the Towne strain of HCMV (10 pfu per 
cell) at 24,48, and 72 hours after infection. Percent acetylation was quantitated by 
phosphorimager analysis.
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presence of a possible repressor element located between -SI and -28.
In order to assess UL98 promoter activation in the presence of all viral or virally 
induced transactivators, HCMV was used to infect cells following transfection with each 
promoter construct. Thus far, data in the characterization of the UL98 promoter stems 
from transient assays only showing activation in the presence of IE viral proteins. 
Promoters are regulated by viral as well as cellular factors. Therefore, it was necessary to 
utilize HCMV in place of constructs which produce only IE proteins. To assess activity 
of UL98 wildtype or mutant promoters in the presence of HCMV, the deletion mutant 
promoters were each transfected into HFF1 cells followed by viral superinfection with 
HCMV (10 pfu per cell). The cells were harvested at 24, 48, and 72 hours post infection 
and processed for CAT activity. At each timepoint, deletions from -194 to -64 were 
activated to the same relative level as the wild-type UL98 promoter (Figure 11).
However, the construct deleted to -51 resulted in a greater than 60% decrease in promoter 
activity at all time points. -34 and -28 deleted promoters were also decreased in activity 
compared to wildtype. The promoter deleted to -85 responded to HCMV infection well 
above the UL98 wild-type promoter at 24,48, and 72 hours. These data provide further 
evidence that the sequences important for UL98 promoter activation lie upstream o f-51.
In summary, the UL98 promoter 5’ regulatory sequences were deleted in a 
stepwise fashion. A model has been developed to illustrate how each deletion mutant 
responded to the IE gene products IE72 and IE86 or HCMV (Figure 12). According to 
the deletion analysis data, promoters deleted to -64 (-194, -136, -85, -64) and tested in the 
presence of IE72 and IE86 resulted in promoter activation equivalent to or above the 
levels of the UL98 wild-type promoter. The construct deleted to -51, however, had a
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FIG. 12. Model of UL98 Promoter Activation. Based on deletion analysis data, the top line represents the UL98 
promoter with designated cis-acting elements. Proposed transacting factors) functional in activation are illustrated 
on the second line as activators (ACT) which may bind the promoter for activation. Each deletion mutant is depicted 
as a solid black line containing putative transacting factors that may bind in response to the deletion generated. The 
phenotypic response observed in HCMV superinfection is labeled to the left of each deletion mutant.
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significant decrease in promoter activity. It is, therefore, suspected that the sequences 
between -64 and -SI play a role in promoter activation. By the removal of additional 
sequences in promoter constructs deleted to -34 and -28, promoter activity was restored 
to wildtype levels as shown in transient data (See Figure 10). In this instance, 
downstream sequences appear to become dominant and a repressed phenotype is 
observed. When superinfecting with HCMV, in the presence of all transactivators, 
promoters deleted to -34 and -28 act similar to -S1 also showing decreased promoter 
activity. From these data, it appears that the addition of virally regulated proteins 
following HCMV infection prevents the return of activation which was observed in the 
-34 and -28 promoter mutants in response to IE proteins.
Mutational analysis of specific response elements in the (JL98 promoter
Analysis of the deletion mutants provides an introductory assessment of the 
region between -64 and -51 as important for UL98 promoter activation. The removal of 
response elements may lead to loss of promoter context and therefore may prevent the 
promoter from functioning in the manner observed when all elements are present and 
properly spatially arranged. The next series of studies were performed to determine 
which element(s) was necessary for UL98 promoter activation. It was, therefore, 
necessary to alter each response element individually while leaving the remaining 
promoter intact lengthwise.
To determine the precise transcription factor binding site(s) important in the 
regulation of the UL98 promoter, substitution mutations were generated in the response 
elements between -85 and -28 (CRE, TCF element, SIE, and yIRE). Because members
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UL98 Mutants in the Full-length Context
pUL98CAT
pCmCAT
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FIG. 13. A schematic representation of the UL98 promoter mutants. Specific sequences within the UL98 promoter were 
mutated by site-directed mutagenesis utilizing the overlapping PCR method. Substitution mutations of various promoter 
elements were changed to EcoR\ restriction enzymes sites (noted as empty grey box). The wildtype promoter sequence 
labeled pUL98CAT shows each element within the promoter as well as the location of the TATA box and the CAP site (+1).
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FIG. 14. Activation of site-directed promoter mutants in the presence of IE proteins. Mutant construct 
DNAs (5 pg) were cotransfected with 5 pg of pSVH into human fibroblasts, harvested at 48 hours, and 
assayed for CAT activity. Duplicate experiments are represented in this figure. All substitution mutations 
were sequenced to verify the presence of the substitution in the proper position and correct orientation.
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of the ATF/CREB family had been implicated in the activation of other early promoters 
(75, 148), the CRE sequence may also play a role in UL98 promoter activation and was 
altered into a mutated CRE (Cm). TCF-1 element was also mutated (Tm), considering 
its location within the 13 bp region (-64 to -51) which was found necessary for UL98 
promoter activity in deletion analysis. A mutation was also generated in the 5' portion of 
SIE (Sm) (-43) oryIRE (Im) (-37) because the elements responsive to interferon (IFN) 
vary widely and have been implicated in promoter activation and repression. A total of 
four substitution mutations were generated: CREm, TCFm, StEm, and ylREm. 
Mutagenesis of the pUL98CAT construct by overlapping PCR allowed for the 
replacement of targeted wildtype sequences with the restriction enzyme site EcoRl 
(GAATTC) (see Figure 10). This restriction enzyme site was chosen because, prior to 
mutagenesis, the promoter region contained no EcoRl sites. As previously described in 
site-directed mutagenesis, two internal oligonucleotides were generated to substitute each 
element (CRE, TCF element, SIE, and yIRE) with an EcoRl site (GAATTC). In the first 
reaction, each internal oligonucleotide was paired with a complementary external primer 
to alter the targeted element. The product from the first reaction served as the template to 
amplify the mutated fragment in a second reaction using only the external primers. 
Insertion of an EcoRl (GAATTC) site not only introduced a mutation at the desired site, 
but also provided a rapid means of screening for the mutation by restriction enzyme 
digestion in the final product.
The mutated PCR product (Figure 13) was digested with Hindlll and the purified 
fragment cloned into a reporter-CAT plasmid. Each individual promoter was 
cotransfected with pSVH (Figure 14) or transfected followed by superinfection with
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FIG. 15. Time course of activation of pUL98CAT and mutants (CRE/TCF element) following 
superinfection with HCMV. Wildtype and mutant promoter/CAT constructs were transfected into 
human fibroblasts on day one and superinfected with HCMV (Towne strain) at 10 pfu per cell on day 
two. Cell extracts were harvested at 24,48, and 72 hours post infection and examined for CAT 
activity. pCmCAT and pCmTmCAT, both containing a mutated CRE site were reduced significantly 
at each time point.
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FIG. 16. Time course of activation of pUL98CAT and mutants (SIE/yIRE) following superinfection with 
HCMV. Wildtype and mutant promoter/CAT constructs were transfected into human fibroblasts on day one 
and superinfected with HCMV (Towne strain) at 10 pfu per cell on day two. Cell extracts were harvested at 
24,48, and 72 hours post infection and examined for CAT activity. plmCAT and pSmlmCAT, both 
containing a mutated yIRE site were reduced significantly at each time point. pSmCAT was reduced at 48 
hours only.
00
82
HCMV (Figure 15,16) and tested in transfection assays. Results from these studies 
showed that in transient assays, the promoters mutated at CRE and yIRE (pCmCAT and 
plmCAT) were reduced in promoter activity only slightly as compared to wildtype, while 
mutations generated at the TCF-1 element and SIE (pTmCAT and pSmCAT) resulted in 
activity similar to wildtype (Figure 14). From these results, it appears that mutating a 
single element only affects promoter activation minimally, meaning two or more 
elements may cooperate to maximally activate the UL98 promoter. In experiments in 
which each individual promoter was transiently transfected followed by superinfection 
with HCMV, promoters containing a mutated CRE or mutated yIRE were reduced greater 
than 50% (Figures 15, 16). These data show that the CRE and yIRE play a role in UL98 
promoter activation, however the cooperative regulation between elements remains a 
possibility.
To determine whether CRE and TCF-1 element cooperate, a double mutation was 
generated. Previous studies have shown that promoter activation via TCF-1 must rely on 
flanking sequences such as CRE (20, 49). Perhaps CRE and TCF-1 element binding 
proteins cooperate in UL98 promoter activation. A double mutation was also generated 
in the SIE and yIRE within a single construct. Two weak IFN response elements side by 
side have functioned together to generate a strong IFN binding site (107, 142). Perhaps 
the SIE and yIRE are present in tandem to function in a similar capacity. Each double 
mutant construct was examined in transfection experiments and assayed for CAT activity. 
Because the promoter containing the CRE/TCF double mutation responded to HCMV 
superinfection much like the CRE only mutant (Figure 15), CRE appears functional in 
activation supporting UL98 promoter regulation by CRE. The SIE/yIRE double
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mutation was significantly reduced similar to the yIRE mutation in the UL98 promoter 
(Figure 16). In superinfection assays, only the promoters containing a single or double 
mutation with CRE or the yIRE significantly reduced promoter activation at all time 
points, supporting a role for CRE as well as yIRE (Figures 15, 16) in UL98 promoter 
gene regulation. Therefore, neither CRE and the TCF-1 element nor the SIE and yIRE 
appear to cooperate in UL98 promoter activation.
From the data above, the cyclic AMP response element (CRE) and the gamma 
interferon response element (yIRE) are major participants in UL98 promoter activation. 
Transfection assays revealed that within the 13 bps between -64 and -51, lies the TCF-1 
element from -59 to -52 and these promoter sequences are necessary for promoter 
activation. The TCF-1 protein, which binds the TCF-1 element, has been shown to act 
not as a transactivator, but instead as a facilitator of DNA bending allowing widely 
separate sites to be brought into close proximity for the activation of the promoter. While 
some transcriptional activators also bend DNA, others lack the ability to bend DNA once 
bound. Perhaps TCF-1 binding sequences aid in the activation of UL98 promoter, and 
influence the role of flanking sequences such as CRE and yIRE in the UL98 
promoter/enhancer region.
Two promoter constructs, p-85CAT and p-64CAT, were shown to have activation 
similar to wildtype (pUL98CAT) in the presence of IE regulatory proteins or HCMV. A 
deletion to -85 consistently resulted in activation at or above the wild-type promoter. A 
deletion further to -64 was slightly decreased in promoter activation but still remained 
close to wild-type levels. Each of these truncated promoter constructs were efficiently 
activated in the presence of viral regulatory proteins (see Figure 11). If the cyclic AMP
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FIG. 17. CRE/TCF element mutations in the context of the -85 truncated promoter following superinfection 
with HCMV. To determine how the mutated elements function in the -85 minimal promoter which has activity 
at or above wildtype levels, constructs were mutated at CRE and TCF-1 element. 4 pg of each mutated CAT- 
reporter constructs, labeled to the far left, was transfecteed into human fibroblasts on day one, followed by 
superinfection with HCMV at 10 pfu per cell on day two. Cell extracts were harvested at 24,48, and 72 hours 
and processed to determine UL98 promoter activity. Graphed data is expressed as percent acetylation.
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FIG. 18. SIE/yIRE mutations in the context of the -85 truncated promoter following superinfection with HCMV. To 
determine how the mutated elements function in the -85 minimal promoter which has activity at or above wildtype levels, 
constructs were mutated at SIE, or yIRE. A double mutation was generated in SIE/yIRE as depicted by element(s) shaded 
in gray. 4 pg of each mutated CAT-reporter constructs, labelled to the far left, was transfecteed into human fibroblasts on 
day one, followed by superinfection with HCMV at 10 pfu per cell on day two. Cell extracts were harvested at 24,48, 
and 72 hours and processed to determine UL98 promoter activity. Graphed data is expressed as percent acetylation.
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response element (-82 to -7S) possesses a regulatory role in UL98 promoter activation, 
the question arises as to why is it possible to delete the cyclic AMP response element (in 
the p-64CAT) and maintain a significant level of promoter activity. To address this 
question, CRE, TCF-1 element, or both were mutated in the context of the -85 and -64 
truncated promoters to assess promoter activity in the presence and absence of CRE .
First, the promoter deleted to -85 was mutated at CRE (p85CmCAT), TCF-l 
(p85TmCAT) element, SIE (p85SmCAT), or yIRE (p85ImCAT) (Figures 17, 18).
Double mutations were also generated (CRE/TCF-1 and SIE/yIRE). After transfections 
followed by superinfection with HCMV into HFF1 cells, the cells were again harvested at 
the respective times (24, 48, and 72 hours postinfection) and assayed for CAT activity. 
p-85CAT served as a positive control allowing for the functional determination of each 
element independent of one another in the context of this truncated promoter construct. 
Figure 17 shows that mutation of the CRE site results in a four fold reduction at 24, 48, 
and 72 hours. The activity of the promoter mutated at the TCF-1 element was reduced 
similarly with a slight increase over the CRE mutation in promoter activity early. In the 
double mutation of CRE and TCF-1 element, promoter activity was reduced even further, 
indicating that a cooperative effort between CRE and TCF-1 element may take place. 
While p85SmCAT had a slight reduction compared to the p-85CAT construct, 
p85ImCAT was drastically reduced (Figure 18). The decreased activity observed in the 
SIE/yIRE double mutation in the context of the -85 promoter is likely due to the yIRE 
mutation since the promoter activity is similar between the p-85ImCAT and the p- 
85SmImC AT constructs. As observed with the mutations generated in the context of the 
full-length promoter, CRE and yIRE are important for UL98 promoter activation.
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FIG. 19. Assessment of mutated elements in the context of the -64 truncated promoter by 
transfection/superinfection assay. To study the effect of the TCF-I element in the presence of the 
activation sequences, TCF-1 element, SIE, and yIRE in addition to the double mutation SIE/yIRE, were 
generated and tested in transfection/superinfection assays. The altered promoters (4 pg) were 
transfected into fibroblasts followed by an infection with the Towne strain of HCMV at 10 pfu per cell. 
Cells were harvested at 24,48, and 72 hours post infection and assayed for promoter activity.
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The UL98 promoter deleted to -64 is considered the minimal working promoter 
because deletions generated to this point have little effect on UL98 promoter activity. To 
determine how the remaining elements (TCF element, SIE, and ylRE) function in the 
absence of CRE, each was mutated in the context of the -64 truncated promoter. Again, 
all promoter-CAT constructs were tested in superinfection assays. The promoter mutated 
at the TCF-1 element in the context of the -64 promoter (p64TmCAT) was responsive to 
viral IE proteins at or above p-64CAT (Figure 19). This observation was unexpected 
considering a deletion of the TCF-1 element reduced promoter activation to a large extent 
(See Figure 10). Slightly reduced activity was observed from p64SmCAT at 24 hours 
postinfection, but this promoter showed activity similar to the wildtype -64 promoter at 
48 and 72 hours. p64ImCAT had a two to three fold reduction whether mutated alone or 
in conjunction with SIE at all timepoints. These data show that a) the UL98 promoter 
functions in the absence of CRE; b) activation still occurs in the presence of a mutated 
TCF-1 element; and c) mutation of the ylRE represses promoter activity thereby showing 
an impact on UL98 promoter activation.
The possibility of a repressor element downstream of -51 in the deletion mutant 
p-51CAT was discussed earlier (See Figure 10). An observation in transient 
transfections in response to IE proteins showed that deletions to -64 resulted in activation, 
while a deletion to -51 resulted in loss of promoter activity (Figure 10). Further deletion 
to -34 and -28 at the minimal TATA box resulted in the return of UL98 promoter 
activation albeit less than the wild-type promoter (Figure 10). Therefore, sequences 
between -51 and -28 confer a repressed phenotype in the context of the -51 promoter in 
response to IE expressing plasmids. Sequences between -51 (just downstream of TCF-1
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FIG. 20. SIE and ylRE mutations in the context of the-51 promoter. Mutations within the SIE, 
ylRE, or both were generated by overlapping PCR mutagenesis in the -51 truncated promoter. The 
constructs were transfected into human fibroblast cells followed by superinfection on day two. 
Again, cells were harvested at 24,48, and 72 hours. Cell extracts were processed and promoter 
activity determined by CAT analysis.
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element) and >28 (TATA box) include two additional elements: sis/PDGF inducible 
element (SIE) at -43 and gamma interferon response element (y-IRE) at -37. The SIE, 
y- IRE, and the TATA box are in tandem. To determine whether the SIE and /or y-IRE 
act as the repressor sequences, mutations were generated in the SIE and /or y-IRE, by 
PCR mutagenesis, in the context of the p-51C AT. Unfortunately, a promoter mutated at 
both the SIE and ylRE could not be generated after several attempts. The mutated 
products were HindW digested, isolated, and cloned into pSVOCATd and tested in 
superinfection assays. Results from these studies revealed that neither the substitution 
mutation in SIE nor ylRE altered the activation state of the promoter deleted to -51 
(Figure 20). All three promoters were unable to be activated in response to HCMV 
infection This indicates that SIE and ylRE are not functional in repression, but instead 
aid in the promoter’s ability to activate the UL98 gene. SIE and/or ylRE may then rely 
on upstream sequences to participate in the activation of the UL98 promoter. As we were 
unable to generate the double mutation in the context o f-5 1, the cooperation of SIE and 
ylRE could not be addressed in the context of the -51 construct.
Analysis of protein-DNA interaction in UL98 promoter activation
Activation of the UL98 promoter by IE proteins alone or by HCMV infection 
indicated that there is a cooperative effort among the elements to regulate the UL98 gene. 
A reduction in activation as a result of a deletion to -5 1 indicated that the sequences 
upstream of -51 play an important role. Therefore, for binding studies, a probe that 
comprises all UL98 promoter elements upstream of -51 was isolated. To assess the 
binding of mock or HCMV infected cell proteins to the UL98 promoter, a 32P labeled
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FIG. 21. Binding of infected cell proteins to a UL98 promoter 
fragment. Nuclear extracts from cells mock infected or infected with 
HCMV (Towne) were isolated at 4,24,48, and 72 hours after 
infection, lanes 2-6. A 32P radiolabelled UL98 promoter probe (-194 
to -51) Narl to MscY) was incubated with nuclear extracts and binding 
was assessed on a 4% polyacrylamide gel. Lane 1 represents the 
probe alone. Binding complexes are indicated by arrows.
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UL98 promoter fragment of 143 base pairs (bps) (-194 to -51) was incubated with nuclear 
extracts isolated at 4, 24,48, and 72 hours after infection (Figure 21). Then, by 
electrophoresis, the probe/nuclear extract reaction was assayed for binding of mock or 
infected cell nuclear proteins to UL98 promoter sequences (complexes are designated by 
arrows). Three complexes formed with mock-infected cell nuclear extracts. Additional 
complexes were observed that were restricted to HCMV infected cell nuclear extracts at 
48 and 72 hours. The 24-hour infected ceil extracts only produced a single complex. The 
72-hour infected cell nuclear extracts provided several complexes, most of which were 
retarded above the two predominant bands visualized in mock and /or infected cell 
extracts and were more abundant. From these data, it was determined that proteins from 
mock as well as HCMV infected cell nuclear extracts are capable of binding the UL98 
promoter (-194 to -51).
Next, a competition-binding assay was used to assess the sequence 
specificity of the protein-DNA interactions observed in Figure 21. To define the 
complexes that were UL98 promoter specific, we carried out competition analysis.
Mock or infected cell extracts isolated at 72 hours were incubated with 50-fold excess 
unlabeled probe (lanes 3,6) as competitor prior to the addition of the 32P labeled 143 bp 
UL98 probe (Figure 22). Analysis of the binding showed that the complexes identified 
by arrows in mock and upper complexes in infected cell extracts were competed off 
(lanes 4,7). A nonspecific competitor of 148 bp was isolated from plasmid pSVOCAT. 
Lacking any UL98 specific sequences, the fragment could not compete off complexes 
formed in mock or infected nuclear extracts. Results from this figure show that the 
complexes indicated by the three top arrows are UL98 promoter specific and HCMV
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FIG. 22. Competition analysis of the UL98 promoter fragment. Mock 
(lanes 2-4) or infected (lanes 5-7) cell extracts harvested at 72 hours after 
infection were incubated with the 32P radiolabeled UL98 promoter probe. 
Lanes 3 and 6 contain reactions incubated with 100 fold excess unlabeled 
specific competitor and lanes 4 and 7 contain reaction incubated with 
100 fold excess 148 bp nonspecific competitor. Lane 1 represents the 
probe alone.
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CRE TCF
V-CCATGCTGCACGAATACGTCAGAAAGAACGTGGAGCGTCTGTTGGCCACGAG-3’ Wild type
S ’ -CC ATGCTGC ACG A AT ACGTC AG AA AG AACGTGG AG-3 ’ CR E
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FIG. 23. CRE/TCF element probes and competitors generated for gel mobility shift assays. The top line shows the 
wild-type sequence contained within the UL98 promoter in the 5’ to 3’ orientation. The elements of interest within 
this portion of the promoter include the cyclic AMP response element (CRE) and the T-cell specific factor (TCF) 
element (underlined). The sequence of the elements were altered utilizing synthetic oligonucleotides. The 
sequence of the wildtype or mutagenic oligonucleotide is indicated by bolded underlined sequence. The names of 
the wildtype (CRE, TCF) or mutant (CREm, TCFm) oligonucleotides are listed to the far right.
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infected cell specific.
The 143 bp UL98 promoter probe (-194 to -51) contained only the first four of 
six UL98 specific promoter elements. To test all the elements in the UL98 promoter for 
binding including those downstream of -SI, a 239 bp fragment (-194 to +45) was isolated 
that contains two additional response elements downstream of TCF element: sis-inducible 
element (SIE) at -43 and gamma interferon response element (ylRE) at -37. The 
32P-labeled fragment of 239 bp was incubated with mock or infected cell nuclear extracts 
isolated at 72 hours. The protein/DNA complexes formed were present in mock and 
infected cell nuclear extracts. Also present were two major slow migrating bands (Data 
not shown). The two top complexes were solely evident in lanes containing HCMV 
infected cell nuclear extracts isolated at 72 hours. Specific binding for the complexes 
could be competed off completely using SO fold excess of an unlabeled 239 bp fragment 
as specific competitor. Therefore, specific binding was also evident utilizing the 239 bp 
probe isolated from the UL98 promoter.
In the next series of experiments synthetic oligonucleotides containing specific 
UL98 promoter response elements were used in the place of isolated DNA fragment 
(Figure 23). These elements were found important in transient assays and were examined 
in binding studies. To assess the binding of proteins to the transcription factor binding 
site CRE, a 32P labeled oligonucleotide of 36 bp containing only CRE was incubated with 
mock or infected cell extracts harvested at 72-hours. A single dominant complex was 
present in mock (depicted by the bottom arrow), while three additional complexes were 
identified in infected nuclear extracts (identified by arrows) (Figure 24). Competition 
analysis using SOx and lOOx excess unlabeled competitor showed that the top complex
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FIG. 24. Binding and competition of the UL98 CRE sequence. A 32P radiolabeled 
36 bp CRE oligonucleotide probe was incubated with mock (lanes 2-5) and infected 
(lanes 6-9) nuclear extracts harvested at 72 hours post infection. Reactions were 
incubated in the absence (lanes 2 and 6) or presence (lanes 3 and 7/ lanes 4 and 8) of 
50 fold and 100 fold excess unlabeled specific competitor (sc) respectively. Lanes 
5 and 9 contain 100 fold excess unlabeled nonspecific competitor (nc) of similar 
size (42 bp). Lane 1 consists of probe only. Binding complexes are indicated by 
arrows.
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FIG. 25. Mutant CRE probe (CREm) in competition assays. 100 fold 
excess of unlabeled competitor in lane 3 (specific), lane 4 (mutant), and lane 
5 (nonspecific) were incubated with nuclear extracts harvested at 72 hours 
postinfection. The 36 bp 32P radiolabeled probe (CRE) was then added.
Lane I represents probe alone and lane 2 contains no competitor.
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was specific and could be competed off (Figure 24, lanes 7 and 8). A nonspecific 
competitor of 42 bp could not disrupt the complex (Figure 24, lane 9). These data show 
that the complex containing CRE is specific for a protein(s) in 72-hour infected cell 
nuclear extracts.
In Figures 21 and 22, specific binding was shown by competition analysis. A 
more definitive way to determine protein-specific binding is to use a fragment identical to 
the probe fragment except mutated in the binding site thereby disrupting function and 
presumably binding. To further confirm CRE specific binding, a 36 bp oligonucleotide 
mutated at CRE (CREm; see figure 23 for sequence) was generated and used as a specific 
competitor. The oligonucleotide was incubated with HCMV infected cell nuclear 
extracts isolated at 72-hours followed by the addition of a 32P radiolabeled CRE probe 
also of 36 bp. This would determine if the specific competition observed in Figure 24 
was due to the presence of a CRE site. The results showed that while the 36 bp 
competitor containing an intact CRE competes off the CRE specific complex (Figure 25 
lane 3), neither a 100 fold excess cold CREm (lane 4) nor a 42 bp nonspecific competitor 
(lane 5) could compete off the CRE specific complex. The observations in Figure 25 
show that an intact CRE must be present for the binding of proteins from 72-hour HCMV 
infected cell nuclear extracts to the 36 bp CRE probe.
Antibody supershift assays are used to identify proteins present in a protein/
DNA complex. To determine the HCMV infected cell protein(s) that bind to the CRE 
site in the UL98 promoter, supershift analyses using CREB/ATF antibodies were carried 
out. The 32P radiolabeled CRE probe was incubated with 72-hour nuclear extracts 
(Figure 26, lane 2), followed by the addition of CREB, ATF-1, or ATF-2 antibody (lanes
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
99
-96 CRE -61
JE3
CREB Ab *
1 2 3 4 5 6 7 8 9
FIG. 26. Identification of protein binding the UL98 promoter. A 32P 
radiolabeled 36 bp probe, shown to the left, was incubated with nuclear 
extracts and further incubated without (lanes 1-4) or with (lanes 5-9) 
specific antibodies for the CREB/ATF protein family. Lanes 5-7 contain 
reactions with increasing amounts of the CREB antibody, and lanes 8 
and 9 contain ATF 1 and 2, respectively. Lane 1 shows probe alone.
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FIG. 27. Confirmation of cyclic AMP response element as a binding protein of the 
UL98 promoter. A 32P labeled CRE probe of 36 bp was incubated with diluted CREB 
protein (Santa Cruz) at 100 pg/ml and was diluted in buffer D at a ratio of 1:100 
(lanes 2-6). Lane 1 represents probe only. The complex was competed with the 100 
fold excess of unlabeled CRE probe (lane 3), mutated CRE (lane 4), and a nonspecific 
competitor (NC) of 34 bp (lane 5). Lane 6 contains CREB antibody for supershift 
analysis.
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5-9). While the addition of CREB antibody in increasing quantity resulted in a supershift 
of the CRE specific complex (lanes 5-7), ATF1 antibody (lane 8) or ATF2 antibody (lane 
9) addition did not result in a supershift, suggesting that one of the proteins binding to 
CRE is CREB protein (Figure 26). Although the ATF-1 antibody failed to show a 
supershift upon addition (lane 8), its presence within the reaction noticeably changes the 
binding profile.
To provide further evidence that the protein binding the CRE sequence was 
CREB, a 32P labeled CRE oligonucleotide probe of 36 bp was incubated with serial 
dilutions of CREB protein (data not shown). A 1: 100 dilution of CREB protein in buffer 
D efficiently showed binding of CREB protein to the CRE sequence (Figure 27, lane 2). 
Competition analysis using excess cold CRE oligonucleotide as a competitor confirmed 
that CREB is binding CRE as binding was disrupted (Figure 27, lane 3). A mutated CRE 
or a nonspecific competitor (Figure 27, lane 4 and 5), could not compete off the complex. 
The addition of CREB antibody (Figure 27, lane 6) resulted in a supershift of the CRE 
specific complex. These data does in fact show that CREB protein binds the CRE site 
within the UL98 promoter.
The element for TCF-1 may play a role in UL98 promoter activation as suggested 
by data in deletion analysis (see Figure 10 and 11). A probe containing the TCF element 
was used in gel shift assays to assess the binding of HCMV viral or virally induced 
proteins to the TCF sequences. A 32P labeled TCF probe (-74 to -45) of 29 bp was 
incubated with 72 hour mock or infected cell nuclear extracts (Figure 28). Several 
complexes were formed; however, four complexes in particular were specific for infected 
cell nuclear extracts (lanes 6-9; indicated by arrows). Competition assays using 100 fold
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FIG. 28. Binding and competition of the UL98 TCF sequence. A 32P labeled 29 bp 
TCF oligonucleotide probe was incubated whth mock (lanes 2-5) and infected (lanes 6- 
9) nuclear extracts each harvested at 72 hours post infection. In conpetition assays, 
reaction were incubated in the absence (lanes 2,6) or presence of competitors for TCF 
(lanes 3,7), mutant TCF (lanes 4,8), or CRE (lanes 5,9). Reactions were run through a 
6% polyacrylamide gel. Lane 1 represents probe alone.
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SlE/vlRE MUTANT PROBES AND COMPETITORS
SIE vIRE 
5’ -GGCC ACG AGCG ACCCCCTCT ATTTAT AT A A-3 * Wildtype
5 ’-GGCC ACG AGCG A ATTCCTGT ATTT AT AT A A-3 ’ Sm
5 ’ -CC ACG AGCG ACGGCiG A ATTCTT AT AT A A.. .CAGC-3’ |m
5 ’ -CC ACG AGCG A ATTCG A ATT CTT ATATA A.. TTCG-3’ Smlm
5’-GCGTCTGrrGGGAATTCGCGAATTCGAATTCTTAT-3’ USI3m
FIG. 29. SIE/ylRE probes and competitors generated for gel mobility shift assays. The top line shows a portion of the 
wild-type sequence containing the sis-inducible element (SIE) and the gamma interferon response element (ylRE). Each 
cis-acting element is bolded with a line below SIE and a line above ylRE to denote the beginning and end of each 
element. Below, four oligonucleotides are represented 5’ to 3’ and bolded letters indicate a mutation from wild-type 
seqhende to an EcoRl site. The site(s) mutated is underlined to the far right. Sm-mutated SIE, Im-mutated gamma IRE, 
Smlm-mutated at SIE and gamma IRE, and USI3m-triple mutation upstream (U) of SIE, at SIE, and at gamma IRE.
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excess TCF unlabeled probe resulted in the loss of three of the four complexes (lane 6; 
two complexes to a lesser extent). More interestingly, the addition of 100 fold excess 
cold CRE competitor resulted in a loss of two complexes (lane 9; the two middle 
complexes to a lesser extent). Both the top and bottom complex were competed off by 
the CRE competitor and the TCF-1 competitor. A mutant TCF (TCFm; see figure 23 for 
sequence) oligo could not completely compete off any of the complexes. These data 
show that in some instances, each protein, CREB and TCF-1 or a TCF-1 related protein, 
may bind the TCF-1 element probe simultaneously or each may bind the promoter 
sequences separately. Studies by others have shown that TCF-1 is made up of four 
different isoforms for different regulatory controls (204). Binding of specific isoforms 
may be represented in Figure 28. Supershift assays using TCF-1 antibody are necessary 
to determine the binding of TCF-1 to CRE and /or TCF-1 element. However, TCF-1 
antibody is not yet available to address actual TCF-1 protein binding.
Assessment of promoter activity from transient transfection data indicated that the 
ylRE is functional in promoter activation in the context of the full length promoter 
(pUL98CAT). The next aim is to utilize gel mobility shift assays to assess binding of 
mock or HCMV infected cell nuclear extracts to the SIE and ylRE sequences which are in 
tandem. Sequences used in the following experiments are represented in Figure 29 as 
synthetic oligonucleotides 5’ to 3’. To first assess the protein/DNA interactions that 
occur at the SIE/yIRE, a 30 bp oligonucleotide end labeled with 32P was incubated with 
mock or HCMV infected cell nuclear extracts both isolated at 72-hours (Figure 30). Both 
mock and infected cell extracts showed very similar binding profiles: one large broad
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FIG. 30. Binding and competition of the UL98 SIE and ylRE sequences. A 32P 
radiolabeled 30 base pair (bp) oligonuclotide probe was incubated with mock 
(lanes 2-4) and infected (lanes 5-7) nuclear extracts harvested at 72 hours post 
infection. Reactions were incubated in the absence (lanes 2 and 5) and presence 
(lanes 3 and 6) of 50 fold excess unlabeled specific competitor (SC). Lanes 4 
and 7 contain 50 fold excess unlabeled nonspecific competitor (NC) of similar 
size (34 bp). Lane 8 contains a control (C) 72 hour extract and lane I consists of 
probe only. Complexes are indicated by arrows.
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FIG. 31. Competition analysis by gel mobility shift assay utilizing mutant 
probes. A 32P 30 bp oligonucleotide was incubated with 72 hour extracts 
were preincubated with 100 fold excess unlabeled competitors: wild-type 
SIE/yIRE (lane 3), or mt-mutated SIE (lane 4), or m2- mutated ylRE (lane 5). 
Lane 6 contains a nonspecific competitor and lane 1 represents probe alone.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
band, which may be several bands migrating close together at midpoint in the gel, as well 
as several lighter bands migrating above (Figure 30, lanes 2,5). Those minor bands 
present in mock extracts seem to be upregulated in 72 hour infected cell extracts. A 50 
fold excess of a 30 bp cold (unlabeled) specific competitor was preincubated with the 
nuclear extracts prior to the addition of the 30 bp labeled probe. While the broad band 
could be competed off although not completely, the bands migrating more slowly (top) 
were competed off well (Figure 30, lanes 3, 6). A nonspecific competitor of 34 bp 
(Figure 30, lanes 4, 7) could not disrupt the bands observed in Figure 30, lanes 2, 5. Lane 
8 is a control (C) extract incubated with the 30 bp SIE/ylRE probe. From these data, it 
was observed that the three lighter bands, which form above the broad band, is specific 
for the SIE/ylRE probe and appeared only in the lanes containing HCMV infected nuclear 
extracts isolated at 72 hours.
To determine the importance of the sequences within the 30 bp SIE/ylRE probe, 
another 30 bp oligonucleotide mutated at the SIE and a 50 bp oligonucleotide mutated at 
the yIRE were used in competition assays as competitors (Figure 31). Competitors (m r 
nu; see figure 29 for sequences) were preincubated with 72 hour infected cell nuclear 
extracts followed by incubation with the 30 bp SIE/ylRE 32P labeled probe. Results in 
Figure 31 show that a mutated SIE/intact ylRE (mi) competes for binding of specific 
complexes more effectively than the competitor containing the intact SIE/mutated ylRE 
(m2) although both compete well under these conditions. It appears that the data, 
observed in this assay, shows that the ylRE may bind a specific regulatory protein(s), 
which falls in line with the role of ylRE in the participation of UL98 promoter regulation. 
SIE binding may be important as well and its potential role should not be overlooked. A
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FIG. 32. Competition analysis by gel mobility shift assay utilizing double and triple 
mutant probes. A 32P 30 bp oligonucleotide incubated with 72 hour extracts was first 
preincubated with 100 fold excess unlabeled competitors: wild-type SIE/ylRE (lane 
3), m,-mutated SIE (lane 4), m2- mutated ylRE (lane 5), m3-doubly mutated SIE/ylRE 
(lane 6), m4-triply mutated upstream of and at SIE/ylRE (lane 7. Lane 8 contains a 
nonspecific competitor and lane 1 represents probe alone.
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FIG. 33. Supershift assays utilizing IRF-3 antibody. A 32P 
radiolabeled 30 bp probe was incubated initially with 72 hour HCMV 
infected cell nuclear extracts (lane 2). Following a 15-20 minute 
incubation, increasing amounts of anti-IRF-3 antibody were added to 
the reaction at 0.5,1.0,2.0, and 4.0 pi (lanes 3-6). Lane 1 contains 
probe alone.
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37 bp oligonucleotide doubly mutated at the SIE and the ylRE (m3), as well as a 35 bp 
oligonucleotide containing three mutations (upstream of SIE, SIE, and ylRE) (nru) were 
also used as competitors in Figure 32. All competitors could compete with varying 
effectiveness. Still again, the 30 bp oligonucleotide containing a mutated SIE and an 
intact yIRE competed best (Figure 31). Therefore, the ylRE is important in protein/DNA 
interactions involving the UL98 promoter with HCMV infected cell nuclear proteins.
Up to this point, a basis for specific SIE/ylRE binding had been established. 
Activation of the UL98 promoter appears to preferentially rely upon ylRE binding rather 
than SIE binding (Figure 32). However, due to the tandem nature of the SIE/ylRE 
sequences, a role for SIE binding cannot be ruled out. Various interferon regulatory 
factors (IRF) and signal transducers and activators of transcription (ST AT) proteins play 
an important role in the activation of interferon (IFN) inducible genes which bind y-IFN 
induced elements (160, 207, 228). Recent studies provided evidence for the IRF-3 and 
CBP proteins cooperating in the regulation of an early promoter through binding an 
interferon stimulated response element (ISRE). To assess whether IRF-3 binds UL98 
SIE/ylRE sequences, an anti-IRF-3 antibody was acquired and used for supershift 
analysis following the incubation of the 32P radiolabeled SIE/ylRE probe with HCMV 
infected cell nuclear extracts isolated at 72 hours. The anti-IRF-3 antibody was 
administered in increasing amounts and found to supershift the SIE/ylRE/ protein binding 
observed in Figure 32 (Figure 33, lanes 3-6). This was in contrast to the 72 hour infected 
nuclear extract lacking antibody (Figure 33, lane 2). These data suggested that IRF-3 is a 
component of the proteins that participate in the regulation of the UL98 promoter.
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FIG. 34. Confirmation of specific IRF-3 binding. Following the 
incubation of a 32P SIE/ylRE 30 bp probe with HCMV 72 hour 
infected cell nuclear extracts (lane 2), 4.0 fxl of IRF-3 antibody was 
added (lane 3). A nonspecific antiserum (prebleed) was used (lane 
labeled pb) to examine the specificity of the anti-IRF-3 antibody. 
Lane 1 is probe alone.
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To confirm the specificity of the IRF-3 antibody supershift, a rabbit antiserum 
was used in direct comparison to anti-IRF-3 in a supershift experiment following 
incubation of 30 bp SIE/ylRE probe with 72 hour HCMV infected cell nuclear extract. 
Unfortunately, as shown in Figure 34, the nonspecific antiserum (rabbit prebleed) 
supershifted just as the anti-IRF-3. These data suggests that the immune reaction was not 
specific. IRF-3 as a component of the trans-acting factors for UL98 promoter activation 
could not be proved conclusively from these data. Further experiments using IRF-3 
protein in the presence of the SIE/ylRE 30 bp probe could provide evidence for IRF-3 as 
a UL98 promoter activation component.
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CHAPTER V 
DISCUSSION 
Activation of the HCMV UL98 Early Promoter
The goals of the project were to isolate the 5’ regulatory sequences of the HCMV 
UL98 promoter which was isolated as a 421 bp fragment (-309 to +112), and to 
characterize its activity in the presence of the immediate early transactivators or virus. 
This approach would allow for the confirmation of the UL98 promoter as an early 
promoter and determine the IE requirement for activation (1). Once the UL98 promoter 
sequences were isolated, the sequences were cloned upstream of a reporter gene 
chloramphenicol acetyltransferase. As presented in figure 3, the promoter was strongly 
activated in the presence of the effectors IE72 and IE86 expressed from the plasmid 
pSVH. This was demonstrated by cotransfection of the plasmid pUL98CAT with pSVH 
(1). Previously, the UL54 polymerase (pol) promoter was characterized and found to 
require IE gene products for its activation (reviewed in reference 186). The promoter for 
the polymerase gene acted as a control for promoter expression. The IE requirement was 
controlled for by the use of the expression plasmid derived from simian virus (SV) 40, 
which lacks the exons for IE1 and IE2 leaving intact the vector backbone called pSVOd. 
Although the UL54 and UL98 genes are expressed at early times, each belongs to a 
different early subclass. While the pol gene is expressed at approximately the same 
levels throughout the course of infection, the UL98 alkaline nuclease gene is expressed at 
low levels (RNA) early and continually increases through late times. The latter 
expression pattern was observed in two other early genes; the pp65 gene and the 1.2 kb 
RNA gene (38, 208). The IE transactivator requirement for the pp65 promoter utilized
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both IE72 and IE86. The 1.2 kb RNA promoter only required the IE86 protein for 
maximal activation. By testing the UL98 promoter in the presence of each IE 
transactivator separately and within the same plasmid, the IE requirement for UL98 
promoter activation was revealed. Both IE72 and IE86 were necessary for maximal 
UL98 promoter activation (Figure 4). The genomic construct, pSVH, activated the 
UL98 promoter most efficiently. pSVH expresses the minor as well as the major IE 
proteins from the MIE gene region suggesting that the MIE minor products likely 
enhance activation of the UL98 promoter.
The HCMV EE72 and IE86 regulatory proteins have been implicated in early 
promoter activation (38, 94). How these viral transcription factors exercise there role in 
the activation of early viral promoters has not yet been revealed. Protein-protein 
interaction has been observed for both IE72 (61, 108, 113) and IE86 (18, 82, 103, 163, 
16S). IE86 is a more promiscuous transactivator interacting with cellular transcription 
factors (CREB, c-jun, ATF-2, jun-B, NFkB, p300/CBP, SP-1, TEF-1, and UBF) as well 
as components of the basal transcription machinery (TFDB, TBP). IE86 binds to its own 
promoter at a cis repression signal (CRS) of 10 AT rich nucleotides between two CG 
residues (CG-Nio-CG) and represses transcription. The phosphoprotein also binds 
specific sequences located upstream of the TATAA box of HCMV early promoters (164, 
165, 180, 182). The sequences within early promoters resemble the CRS of the MIE 
promoter. However, the CG residues are at both ends of a 14 nucleotide sequence that is 
AT rich internally (180).
The UL98 promoter has a CG-Nm-CG sequence from -102 to -85 positioned 
adjacent to the CRE site from -82 to -75. Also overlapping the CRE and the TCF-l like
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element are two CG-N16-CG sequences (-85 to -67, -67 to -47). The nucleotides 
sandwiched between the CG residues ranging from 9 to 14 residues fits well with the 
thought that IE86 may recognize structural features of the DNA more than specific 
sequences (180). Because IE86 is known to interact with the basal transcription 
machinery as well as with CREB, perhaps IE86 links CREB and TBP or TF11B for 
transcription initiation. IE86 could interact with CREB protein that binds CRE or an 
IE86 binding site within the UL98 promoter. IE86/CREB interaction could be tested 
indirectly by assessing the ability of IE86 antibody to supershift the CREB/UL98 specific 
CRE complex in gel mobility shift analysis. This will suggest that IE86 is a part of the 
complex binding CRE. Competition experiments could test the actual binding of IE86 to 
CREB. Bands retarded by a CREB/ CRE complex could be enhanced or stabilized by the 
addition of purified IE86. Again, anti-IE86 could be added to further retard the complex 
indicative of IE86/ CREB interaction. Similar experiments using UL98 promoter specific 
IE86 binding sites as the DNA probe could also be employed. Neither has been 
demonstrated thus far. This may provide some indication as to why removal of 
sequences beyond -64 results in the decrease of UL98 promoter activation.
The subclassification of early genes is based upon pattern of expression 
throughout the course of infection. Because the RNA levels of the UL98 gene increased 
throughout the course of infection in northern blot analysis (1), promoter activation was 
also assessed via analysis of CAT activity at 24, 48, and 72 hours postinfection. The 
UL98 promoter was transfected into cells followed by HCMV infection. Transient 
transfection data showed that the UL98 promoter was additionally stimulated well above 
activation levels observed in the presence of viral MIE proteins (24 hours) and increased
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through late times (48 and 72 hours) (see figure 11).
Over the course of infection, UL98 promoter activation increased at 24,48 and 72 
hours (see figure IS and 16; pUL98CAT). These data were expected considering that 
previous studies showed that the RNA levels increased in a similar manner (I).
However, in figure 11, activation of the UL98 promoter seems to peak at 48 hours and 
decrease slightly at 72 hours. The transcriptional regulation of the UL98 promoter was 
assessed by determining the transcriptional initiation of the chloramphenicol 
acetyltransferase (CAT) gene under the control of the UL98 S’ regulatory sequences.
The expression of the CAT gene is monitored by measuring the enzymatic activity of the 
CAT protein. By CAT analysis, it is possible to assess the promoter’s ability to mimic 
accurately the expression pattern of the endogenous gene (UL98 gene).
While there are several advantages for assessing promoter regulation indirectly 
using a reporter assay, a few limitations should be noted. In transient transfection assays, 
plasmids exist in an artificial configuration and the copy number may lead to inactivity or 
aberrant function of specific control elements. The plasmid is also episomal and not in 
the proper chromosomal configuration. The promoter may function in an aberrant 
manner. Another disadvantage is the stability of the CAT mRNA. The CAT protein is 
considered quite stable throughout the course of the reporter assay with a half-life of 
approximately 50 hours in mammalian cells (9, 111). However, CAT mRNA is present 
at low levels and is very difficult to analyze directly. If CAT message cannot be 
detected, there is difficulty in stating whether the level of CAT enzyme appropriately 
reflects the initiated message from the promoter. The stability of the mRNA was not 
accounted for in these analyses. To accurately assess transcription in the artificial contact
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of the transient transfection assay would require the use of a procedure that will measure 
transcription initiation from the endogenous gene; the nuclear run on assay. This assay 
would provide a measure of the frequency of transcription initiation independent of the 
effects of mRNA stability.
Deletion Analysis of the UL98 Promoter
The next question addressed in this study was to determine which response 
elements upstream of the CAP site were important in UL98 promoter activation (1, 223). 
The question was approached by deleting one element at a time beginning at the S’ end 
and in a stepwise manner progressively shortening the promoter to the TATA box. As 
compared to the wildtype promoter only one of nine deletions drastically reduced 
promoter activity. A deletion from -64 to -51 reduced promoter activity by more than 
70% in the presence of HCMV IE regulatory proteins (Figure 10). Sequences between 
-64 and -51 have a putative T-cell specific factor (TCF-1) element on the negative strand 
suggesting this transcription factor binding site may play a significant part in the 
activation of the UL98 promoter. In the presence of the virus (HCMV), the identical -5 1 
deletion drastically reduced promoter activation by as much as 80% at all time points (24, 
48, and 72 hours) (Figure 11). Promoters deleted to -34 and -28 were also reduced 
significantly.
The TCF-1 binding site is homologous to the LEF-1 site (TCFla) found in the 
TCRa chain gene promoter (20, 202). The LEF-1 (TCF-la) protein has high homology 
to the TCF-1 protein (approximately 97%) and each contains a DNA binding sequence 
referred to as the HMG domain (202). In other promoters, the ability of a TCF-1 binding
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site to support transactivation is context specific (49, 205). Full activation of a promoter 
with a TCF-1 site depends heavily on the simultaneous presence of other sites 
(ATF/CREB, core-binding factor/PEBP2a, and ETS-1) at defined flanking positions 
(49). The TCF-1 protein has been shown to act not as a transactivator, but rather a 
facilitator of DNA bending allowing widely separate sites to be brought into close 
proximity for the activation of the promoter (49). In the UL98 promoter, the TCF-1 
element (-59 to -54) is flanked by a CRE site (-82 to -75) upstream of the TCF-l element 
and two sites downstream; the SIE (-43 to -38) and the ylRE (-37 to -30).
Response elements for the cyclic AMP response element binding protein/ 
activation transcription factor or CREB/ATF family of proteins have been implicated in 
the regulation of other HCMV early promoters (23, 89, 152). Activation of the UL54 
promoter relies on an ATF-1 binding site for the regulation of the polymerase gene.
UL112-113 (2.2 kb RNA) promoter activation depends upon a CREB binding site as 
well. The regulatory region of the US 11 early gene contains a CREB and an ATF site, 
both of which are important in the activation of US 11 gene expression. Although UL54, 
UL112-113, US11, and UL98 are all classified as early genes, each varies in its 
expression pattern. The genes for the UL54 and the UL112-113 are of the subclass which 
maintains a constant amount of expression throughout the course of infection. The UL98 
gene expression increases from early to late times, while US11 gene expression is 
downregulated late in infection. CRE/ATF sites, therefore, may be used differently in the 
regulation of gene expression. Deletion of the UL98 promoter to -64 (p64CAT), which 
removes the CRE, did not significantly impact promoter activation, but only reduced 
activity of the UL98 promoter slightly at each timepoint in superinfection assays (Figure
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11). Activation levels were at or above wildtype levels in transient assays (Figure 10). 
However, mutation of the CRE site resulted in a drop in promoter activity. These data 
showed that the CRE site in the UL98 promoter may also play a role in promoter 
activation but may require the assistance of other response elements within the promoter.
Sequences downstream of the TCF-1 element, between -5 1 and -28 (TATA box) 
include two additional elements: the sis/PDGF inducible element (SIE) at -43 and the 
gamma interferon response element (yIRE) at -37. In the absence of upstream sequences, 
as observed in the -S 1 promoter, a repressed phenotype is evident in transient assays. 
Further deletion to -34 or -28 at the minimal TATA box resulted in the return of 
promoter activation. It was therefore necessary to determine if repression, observed with 
the -51 promoter, stems from the loss of TCF-l element or the presence of an isolated 
SIE/yIRE . In response to HCMV, the -51 promoter activity remained significantly 
diminished. Promoters deleted to -34 and -28 were also significantly reduced, unlike in 
transient assays. It was noted however that in both cases (transient and superinfection) 
the -34 and -28 promoter activity was above -5 1 promoter activity. The return of 
promoter activation could be the result of a repressor protein (s) binding to the SIE and/or 
yIRE in the absence of the upstream sequences. On the other hand, a multiprotein 
complex that binds upstream sequences to -64 may be responsible for activation, 
becoming unstable due to the absence of sequences upstream. Further deletion to -51 
then allows for sequences downstream of the TATA box to become dominant and play a 
role in the activation of the promoters deleted to -34 and -28. An ISRE (interferon 
stimulated response element) site (GGGAAAGGCAACAG) from +81 to +95 has 
similarities to the consensus ISRE (GGGAAACCGAAACTGAA) and may play a role.
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The 5’ regulatory sequences beyond the -28 TATA box, however, were not addressed in 
these studies.
Analysis by Substitution Mutation (CRE and TCF-1)
To this point, it appears by deletion experiments that sequences between -64 and 
-S 1 facilitate the transactivation process, possibly via DNA bending through the putative 
TCF-1 element. As previously mentioned, some early promoters of HCMV as well as of 
other herpesviruses (13, 43, 173) utilize a CREB/ ATF site in the regulation of early gene 
expression. For this reason, the HCMV UL98 promoter was next mutated at the TCF-1 
site or the CREB site or both mutated simultaneously in the context of the full length 
promoter (-309 to +112). Studies in which all promoter elements remain full length 
(from -309) as wildtype except where specifically mutated may provide a more accurate 
assessment of promoter activation. The next series of experiments involve transfection of 
wildtype or mutant promoter constructs followed by infection with HCMV. Results 
clearly showed that the mutation of the CRE site alone or in conjunction with the TCF-1 
site diminished UL98 promoter activity by greater than 60% (Figure 15). The promoter 
mutated at the TCF-1 site was only slightly reduced; an unanticipated result considering 
the removal of this element by deletion nearly abrogated UL98 promoter activity. In this 
case, CRE appears necessary while the TCF-1 element may have an accessory role. This 
falls in line with the role of CRE in transactivation and TCF-1 element in facilitating 
transactivation. Maintaining this line of thinking, recall that in previous studies in T- 
cells, a TCF-1 element was necessary to bring flanking sites bound by transactivators into 
close proximity for the activation of the TCRa chain gene promoter (20, 49, 206).
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The cyclic AMP response element binding (CREB) protein, which binds the CRE 
site, is a member of the b-zip family of proteins that binds DNA as a homodimer or 
heterodimer (CREB 1,2 or ATF 1,2,3,4, or CREM). A variety of b-zip proteins are known 
to function in DNA bending as well (139, 149) and different protein dimers induce 
distinct DNA bends (87). Jun and Fos members bend DNA toward the major groove 
while ATF-2 dimers bend DNA toward the minor groove. CREB and ATF-1, however, 
which favor binding to the CRE site over an AP-1 site, do not induce significant DNA 
bending. This suggests that some b-zip proteins do not induce directed DNA bending.
The CRE site alone bends intrinsically toward the major groove, and interaction with a 
CREB/ATF protein result in the overall “straightening” of the DNA (121, 139). This is 
possibly the case within the UL98 promoter. Because the CRE may be straightened by 
the binding of a CREB/ATF family members (CREB 1-2, ATF 1-4, or CREM), it is 
suspected that the promoter relies on the presence of the TCF-1 site to bend the DNA in 
order for other elements bound by proteins to associate and result in optimal promoter 
activation.
As previously mentioned, the cellular protein CREB and the viral regulatory 
protein IE86 interact and function in early promoter activation (163, 180). Although the 
ability of IE86 to bind to the UL98 sequences was not tested, the supershift studies 
described above could have been extended to determine if IE86 protein was present in the 
complex bound to the UL98 CRE sequence. Incubation of HCMV infected cell nuclear 
extracts with the full length UL98 promoter fragment or the UL98 CRE sequence 
followed by the addition of antibody directed against IE86 might result in a supershift 
suggesting the presence of IE86 protein (10).
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Do cellular and viral proteins cooperate in the activation of the UL98 promoter?
In the gel shift analyses, mock infected cell nuclear extracts incubated with each fragment 
or ds oligonucleotide used in gel mobility shift analysis resulted in the formation of some 
protein/DNA complexes visualized as bands (see figure 21 and 22). Upon virus 
infection, HCMV infected cell nuclear extracts formed bands additional to those observed 
in the absence of virus. Those complexes formed in the absence of virus are likely the 
result of cellular transcription factors binding sites specific for them. Virus infection 
seems to upregulate cellular proteins and supply viral transcription factors. Several 
protein/DNA complexes are observed in this case. In the presence of viral or virally 
induced regulatory proteins, activation of the UL98 early promoter is observed. It is the 
complex cooperation of both that provides the activation of the promoter.
In figures 24 and 25, although both gel mobility shift assays utilize the same 32P 
36 bp radiolabeled probe as well as the same HCMV infected nuclear extracts isolated at 
72 hours post infection, the protein/DNA interactions observed are quite different. The 
differences in binding can be explained by variables other than probe and nuclear extracts 
used. The gel in figure 24 was run in IX TBE and the gel in figure 25 was run in one- 
half X TBE. The use of higher ionic strength buffer systems can enhance the resolution 
of protein-DNA complexes. This would explain the better resolution of figure 24 over 
figure 25. The increase in binding complexes observed in figure 24 may have resulted 
from a second variable: the use of nonspecific carrier DNA. While a poly (dl-dC)- poly 
(dl-dC) alternating copolymer was used at 5 ul per reaction in figure 24, only 2ul was 
used per reaction in figure 25. In higher ionic strength, a smaller amount of bulk carrier 
DNA is required to abolish nonspecific binding of proteins to the probe. However, figure
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24 contains both a high ionic strength buffer as well as an increased amount of carrier 
DNA. Therefore, an increase in binding is evident.
CREB was identified in gel mobility shift assays as a protein that binds CRE in 
the UL98 promoter. To identify the protein that binds specifically, a CRE specific 
oligonucleotide probe of 45 bp was generated to test in gel mobility shift assays.
Through a series of gel shift assays utilizing 72 hour HCMV infected cell nuclear extracts 
or CREB protein, binding at the CRE site at -82 was determined to be the protein CREB 
(Figures 26 and 27). Because antibody supershift binding studies showed that neither 
ATF-1 or ATF-2 bound to the CRE site utilizing anti-ATF-1 or anti-ATF-2 (Figure 26), 
CREB likely binds the CRE site as a homodimer. Heterodimeric formation of CREB 
with another CREB/ ATF family member or with the AP-1 (JUN or FOS) transcription 
factor family remains a possibility. It has been suggested that the ATF/CREB family 
members could be activated through phosphorylation via the ERK signaling pathway 
following HCMV infection (152). Increased phosphorylation through this signal 
transduction pathway appears to compromise phosphatase activity following virus 
infection, which in turn means sustained transcription factor activity via ERKs.
Therefore, viral gene expression is extended and a productive viral infection is 
maintained (152).
The ATF-1 antibody failed to supershift as did the CREB antibody. However, its 
altered complex formation of retarded bands does not rule out the possible presence of 
ATF-1 protein or the supershifting by ATF-1 antibody. The protein/DNA complex was 
formed prior to the addition of antibody in figure 26 (lane 2). Not visualizing a supershift 
in lane 8 led to the conclusion that ATF-1 does not bind. Because of the inability to
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resolve the binding complexes more precisely in this gel, the ATF-1 antibody may 
supershift but is not definitively discernible. To determine if ATF-1 is a participant in 
binding to the UL98 promoter, an alternative test to determine if the protein binding the 
UL98 promoter is ATF-1 is to block the complex formation observed in lane 2. The 
addition of antibody prior to incubation of the probe, thus binding of the ATF-1 antibody 
to the protein (possibly ATF-1), would prevent the formation of the complex in lane 2. 
ATF-1 antibody might also be cross-reacting with other ATF//CREB family members 
(CREB, CREM, ATF-2: see “antibodies” in Materials and Methods section) thereby 
binding the CREB protein and again blocking complex formation.
It appears that CREB may also bind the putative TCF-1 element in the UL98 
promoter. In competition assays involving the TCF-l element and 72 hours HCMV 
infected cell nuclear extracts, specific binding could be competed off not only by cold 
TCF-1 specific excess competitor (figure 27), but also by cold CRE excess competitor. 
This suggests that CREB and the protein(s) which bind the putative TCF-1 element may 
interact. The implication that UL98 promoter activation requires DNA bending which is 
instrumental in increasing protein-protein interaction may mean that proteins other than 
CREB and the proposed TCF-1 are interacting. Therefore, the interaction between CREB 
and putative TCF-1 may be indirect and require the participation of a protein(s) capable 
of binding each. An important factor that must be stated is the fact that the TCF-1 has 
not been identified in fibroblast cells, but TCF-1 has been exclusively detected in T-cell 
lineages only (202). HCMV has not been shown to activate TCF-1. However, because a 
number of factors ( SRY, UBF, and mammalian testis-determining factor) have been 
identified (49, 202) that share the HMG box functional in DNA binding, perhaps a
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fibroblast specific protein with activity similar to TCF-l could be involved in activating 
the UL98 protein in fibroblasts.
To better understand the cooperation between CRE and TCF-1 element in UL98 
promoter regulation, additional experiments that involve mutated elements were carried 
out, this time in the context of truncated promoters. Previous studies showed that in the 
presence of viral regulatory proteins the promoters deleted to -85 and -64 were activated 
to wildtype promoter levels. The question arose as to why a promoter lacking CRE (p- 
64CAT) functions similar to a promoter with CRE present (p-85CAT), if CRE is in fact 
necessary for UL98 promoter activation (see figure 10; results section). To answer this 
question, the same CRE and/or TCF-1 element were mutated in the context of the -85 
promoter containing CRE or in the context of the -64 promoter in the absence of CRE. 
The promoter activity from the construct mutated at CRE in the -85 promoter provided 
similar results as when mutated within the full length construct. The -85 promoter 
mutated at CRE was significantly reduced at 24, 48, and 72 hours. The promoter mutated 
at TCF-1 element was reduced at 48 and 72 hours but was comparable to the p-85CAT 
control at early times. The differences between the effects of mutations in the context of 
the wildtype promoter and in the context of the -85 promoter indicates that the upstream 
elements previously mentioned (SRE and E2F) may play a role in the activation of the 
UL98 promoter with reference to the TCF-1 element but not CRE. Under these 
conditions, CRE and TCF-l element remain significant players in the activation of the 
UL98 promoter.
In the context of the -64 promoter, there is a gradual decrease in promoter activity 
as each element 5’-3’ is mutated toward the TATA box. The promoter activity observed
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with the promoter mutated at TCF-1 element in the context of the -64 promoter 
(p64TmCAT) was not expected. This promoter not only lacks the CRE site (-82), but 
also contains a nonfunctional TCF-1 site. The inactivation of the two primary elements 
would likely result in a significant decrease in promoter activity. However, the activation 
of the p64TmC AT construct is low at early times, but is well above the p64CAT control 
construct at late times. Previously, it was mentioned that the TCF-1 element is present on 
the negative strand. There is currently no direct evidence that the element is functional in 
the opposite orientation, van de Wetering et. al. assessed the binding specificity of a 
TCF-1 element in the CD3-e enhancer by methylation interference footprinting utilizing 
the positive and negative strand DNA of the TCF-1 element (205). The A and G 
interactions were monitored as an indication of nucleotides in contact with the TCF-1 
protein. While contacts were made with the A and G of the positive strand, no contacts 
were observed with A and G on the negative strand (205). Another possible explanation 
is that the mutation generated in the TCF-1 site (TCTGTTGGto GAATTCGG) is not 
sufficient to disrupt TCF-1 binding. In this case, additional mutations in the TCF-1 
element could have addressed this issue. Gel mobility shift analysis using the UL98 
promoter specific TCF-1 element probe, however, showed specific binding with HCMV 
specific protein(s) from infected cell nuclear extracts (Figure 28). The TCF-1 element 
could compete off the specific binding while the mutated TCF-1 element could not. This 
data suggests that the mutation generated is indeed able to disrupt binding. TCF-1 
proteins have been shown to bind specifically to a pyrimidine-rich DNA sequence, 5’- 
CTTTG-3’ (202, 205, 206,211,213). The TCF-l □ (LEF-l) was originally identified as 
a family of 53-55 kD DNA-binding proteins that bind specifically to a motif (5’-
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CCTTTGAA-3 ) which was present in the TCRa enhancer and the HTV enhancer (20, 
213). Although the sequence is no longer pyrimidine rich, a 5’-CTT-3’ still exists in the 
core of the element after replacement with an EcoRl site. These data showed that the 
UL98 promoter is likely dependent upon other transcription factor binding sites as well as 
CRE and TCF-1-like element.
Analysis by Substitution Mutation (SIE and yIRE)
Downstream of the TCF-1 binding site were two additional sites: the sis-inducible 
element (SIE) and the gamma interferon response element (yIRE). Each was substituted 
with EcoRl sites or both mutated in a single plasmid and transfected into cells followed 
by HCMV infection. When analyzed at 24,48, and 72 hours post-infection for promoter 
activity as compared to wildtype, mutation of the yIRE and the double mutation of SIE 
and yIRE within the promoter resulted in activation 70% below the wildtype promoter 
remaining decreased throughout the course of infection (Figure 16). While the SIE 
mutation in the promoter was decreased slightly at 24 and 48 hours, the promoter activity 
appears to recover to wildtype levels by 72 hours. These superinfection assays showed 
that the yIRE and perhaps with the assistance of the SIE also participate in UL98 
promoter activation. Mutations of the SIE and/or yIRE in the context of the -85 promoter 
provided similar results to the identical mutations in the context of the wildtype promoter 
(Figure 18).
The sis inducible element (SIE) has been best characterized in the c-fos promoter 
(60, 158, 159). It is defined by its ability to bind the sis inducible factor (SIF), a PDGF 
or EGF inducible transcription factor. Studies have shown that while the serum response
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element (SRE) is the prominent sequence in c-fos promoter transcription in vitro, the SIE 
contributes in vivo to c-fos promoter transcription (159). The c-fos promoter is activated 
independent of the SIE when serum induced, and PDGF and EGF latently induce the 
promoter in certain cell types (60, 158). These studies on the SIE reported that agents 
(growth hormones) activate independent responder elements or a set of elements, and so 
the implication is that multiple independent enhancer elements control c-fos transcription.
The gamma interferon response element (yIRE) is a member of a family of 
enhancers that determine the induction of many genes by interferons (IFNs) (reviewed in 
reference 35). Many variations on a theme are represented here. The element and similar 
sequences have been referred to as the gamma interferon activation site (GAS) (134), 
gamma interferon response element (yIRE) (45, 107, 161, 197), and the gamma interferon 
response region (GRR) (34). Interferons function to inhibit virus growth and are 
represented by two types: Type I interferon (IFN a,P) and Type II interferon (IFN y) 
(reviewed in reference 207). Type I and II interferons induce the activation of a family of 
transcription factors called the signal transducers and activators of transcription (STATs). 
There are six known STATs to date and upon activation form dimers or heterooligomers 
depending on induction initiated by IFN a,p or IFNy (160). STATs which are activated 
in response to IFN a,P form a complex of interferon stimulated gene factors (ISGF3) 
which consist of STATs 1-3 (91/84 kD, 113 kD, and 48 kD) (161). The ISGF3 complex 
enters the nucleus to bind the interferon stimulated response element (ISRE) in the 
promoter/ enhancer region of an activated gene. IFN y utilizes the same ST AT pathway, 
but can also rapidly induce a second ST AT complex called the gamma interferon 
activation factor (GAF). In this instance, GAF consists of a ST AT 1 homodimer (91-kD
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ST AT protein) that binds the gamma interferon activation sequence (GAS) (34). It 
should be noted that the SIE is considered a GAS type element and the SIF shares 
important attributes with STATs.
More recently a family of proteins called the interferon regulatory factors (IRFs) 
have been described and are candidates for virus-induced ISRE activation (228). There 
are at least nine IRF family genes in human and mouse. IRF-1 and -2 were identified as 
transcriptional activator and repressor, respectively (59, 124). IRF-3 was identified by 
primary sequence homology to the family and shown to be expressed ubiquitously in 
human tissues (8 ). Expansion of this group of interferon responsive proteins now 
includes ISGF3y/p48, ICSBP, PIP/ICSAT/IRF-4, IRF-5, IRF-6 , and IRF-7 (8 , 59, 124). 
Interferon regulatory factors have also been implicated in early promoter regulation.
IRF-3 has the potential to be activated directly by virus infection (131). Additional 
studies provide strong evidence that IRF-3 and IRF-7 proteins are required for the 
activation of virus inducible genes (214). IRF-3 and IRF-7 are present in a complex in 
uninfected cells. In this state, they can neither bind DNA nor activate transcription.
Virus infection leads to an increase in the phosphorylation of IRF-3 and possibly IRF-7. 
This posttranslational modification induces cytoplasm to nucleus translocation where the 
IRF-3 and IRF-7 proteins are able to bind the promoters of virus inducible genes. The 
association of IRF-3 with the coactivator p300/CBP following nuclear translocation 
allows for binding to DNA and participate in the activation of IFN and IFN-stimuIated 
genes (8 , 228, 131). This may, in turn, play a role in the HCMV replication. As 
previously mentioned, y-IFN has been described as having antiviral effects, but has also 
been shown recently to positively influence virus replication as well (see Pathogenesis of
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HCMV disease in Introduction). ISG’s are activated without the need for prior de novo 
protein synthesis. Protein complexes preexist in a latent form in cell and are activated by 
phosphorylation and initiate transcription of ISG’S for antiviral defense. On the other 
hand, ISG’s can induce gamma IFN thereby causing the differentiation of monocytes to 
macrophages which increases the cells susceptibility to virus infection.
A synthetic oligonucleotide of the sequences containing the yIRE and the SEE 
were generated and used as a probe to determine if protein(s) from HCMV infected cell 
nuclear extracts specifically bind this sequence. Because the CRE and TCF- 1 element 
were well isolated by flanking sequences on both sides, it was feasible to generate an 
oligonucleotide of adequate size or length that only contained the element under study 
for use as a probe in gel mobility shift analysis. The SIE and yIRE are six and eight bp in 
length, respectively and are in tandem with the TATA box. In order to test these 
sequences in binding assays, the approach was to assess protein-DNA interaction using a 
30 bp oligonucleotide which consisted of both transcription factor binding sites along 
with the TATA box. In figure 29, specific binding to the SIE/yIRE probe was observed 
when using HCMV infected cell nuclear extracts preincubated with excess unlabeled 
specific 30 bp probe containing SIE and yIRE. The specificity of SIE/yIRE binding (see 
figure 30) was further determined by testing the binding requirement. Did binding 
preferentially depend upon one site over the other, or were both sites necessary for the 
specific interactions observed thus far? In figure 30, competitor oligonucleotides mutated 
at SIE or yIRE each competed off specific complexes. Interestingly, the presence of a 
mutated SIE and an intact yIRE provided the most efficient competition. This data 
placed an emphasis on the importance ofyERE in protein-DNA interaction and possibly
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in UL98 promoter activation. UL98 promoter activation experiments utilizing site 
directed mutagenesis to determine important m-acting sequences revealed that although 
SIE and/or yIRE mutations decreased UL98 promoter activity, the yIRE mutation 
significantly impacted activity throughout the course of infection. Therefore, yIRE 
binding supports a role for yIRE observed in transfection experiments.
Lastly, an attempt was made to identify the protein(s) that bind with specificity to 
the SIE/yIRE probe. Previous studies demonstrated that when the SIE 
(AGTTCCCGTCAAT) of the c-fos promoter was tested for binding in gel shift assays, 
three distinct SIF complexes were identified (159). Three SIF complexes (A-C) were 
formed and determined to consist of a ST AT 3 homodimer (A), a ST AT 1,3 heterodimer 
(B), and a STAT I homodimer (C). GAS selected for optimal binding in vitro of STAT 
1,3, and 4 have dyad symmetries that are extended towards the center (TTCN2.4GAA) 
(35). The UL98 promoter SIE/yIRE sequences do not resemble the dyad symmetry 
motif. GAS may also have an extension of the palindrome away from the center of 
symmetry. A well documented example of this extension of palindrome is the m67 SIE 
mutant oligonucleotide (also called a high affinity SIE) which converts a weak STAT 1,3 
binding site to a strong one (159). On the other hand, the GAS in the two mig (monokine 
of interferon gamma) chemokine gene promoter contains a weak binding site for STAT 1 
(TTANNNTAA) (35). Evidence exists for weak sites in tandem to generate a strong site. 
Since neither the SIE nor the yIRE is a consensus binding site, experiments were 
approached from the standpoint that the two sites likely cooperate to generate a strong 
(er) STAT binding site.
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Interferons (IFNs) are a large family of multifunctional secreted proteins involved 
in antiviral defense, cell growth regulation, and immune activation (228). Some IRFs are 
linked to IFN signal transduction, while others are induced or activated by IFN, and still 
others are involved in IFN gene regulation. Navarro et al. have shown that HCMV 
infection results in IRF-3 complexing with the transcriptional coactivator CREB binding 
protein (CBP) and stimulates transcriptional activation through an ISRE controlled by the 
ISG54 gene (131).
An IRF-3 antibody was used in supershift assays following the incubation of the 
30 bp SIE/yIRE probe with 72 hour HCMV infected cell nuclear extracts (Figure 33). 
Increasing concentrations of anti-IRF-3 antibody supershifted one band consistently 
suggesting that IRF-3 may be a component of the transacting factors binding the UL98 
promoter. To confirm this specificity, the anti-IRF-3 antibody supershift was compared 
to rabbit antiserum prebleed (Figure 34). Unfortunately, a supershift still occurred in the 
presence of a nonspecific antiserum. Additional experiments are necessary to confirm 
this data, perhaps by the use of IRF-3 protein with the SIE/yIRE probe and the use of 
IRF-3 antibody that has since become commercially available (Santa Cruz 
Biotechnology, Inc.).
IRF-3 is constitutively expressed in a variety of tissues and has a unique feature in 
response to virus infection. IRF-3 remains in a closed conformation in the cytoplasm of 
uninfected cells. However, following virus infection or dsRNA, IRF-3 is phosphorylated 
and a conformational change permits the translocation of IRF-3 into the nucleus. The 
phosphorylated IRF-3 then enters the nucleus accompanied by the coactivator CBP.
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Because of the protein-protein interaction that occurs between the IRF-3 and the 
coactivator CBP, an anti-CBP antibody could supershift the SIE/yIRE probe bound by a 
phosphorylated IRF-3.
Thus far, site specific mutagenesis has allowed for the identification of three key 
sequences important for the activation of the UL98 promoter: the cyclic AMP response 
element, the putative T-cell specific factor element, and the gamma interferon response 
element. Taken together, mutagenesis studies indicated that the UL98 promoter was 
activated primarily by CRE and yIRE although clearly the unique arrangement of all four 
transcription factor binding sites upstream of the TATA box collectively contribute to the 
regulation of the UL98 promoter. Each was reduced significantly in infection 
experiments at particular time points possibly where they have the greatest impact.
All of the observation discussed above relate to the central objective of this 
project: that is, to characterize the HCMV UL98 promoter by the assessment of the cis- 
acting elements and transacting factors utilizing extensive site directed mutagenesis and 
CAT-reporter constructs. The UL98 promoter region as well as promoters containing 
mutations which unveiled the importance of the CREB binding site will be analyzed in 
the context of the viral genome as a future continuation of these studies.
Significance of These Studies and Future Directions
The goal of this project was to identify the mechanisms essential for regulating 
an early gene in HCMV infected cells. In the studies described above, we attempted to 
identify viral and cellular proteins important for UL98 promoter function as well as 
promoter sequences through which these proteins act. Transient expression assays were
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used to determine viral promoter activity. These studies required the use of the reporter 
gene chloramphenicol acetyltransferase under the control of the UL98 early viral 
promoter. The promoter-reporter construct was cotransfected with expression plasmids 
encoding HCMV IE transcriptional regulatory proteins or cotransfected followed by 
infection with HCMV.
In results from transient transfection experiments in the presence of HCMV MIE 
proteins or in the presence of virus on the regulation of the UL98 promoter, two elements 
play an important role in activation. Our studies, thus far, have identified the cyclic AMP 
response element (CRE) as the primary regulatory element because it enhances promoter 
activation at 24,48, and 72 hours. UL98 promoter activation is decreased by half in the 
presence of a mutated CRE at all time points. By assessing protein/DNA interaction, it 
was determined that the cellular factor CREB binds to CRE site in the UL98 promoter. 
The yIRE also plays a role however relies upon the presence of the upstream promoter 
sequences in the regulation of the UL98 early gene. Sequences from -64 to -51 may 
facilitate the complex interplay between viral and cellular proteins. While CRE appears 
important throughout the course of infection possibly exerting its regulatory function at 
both early and late times, yIRE seems to impact the UL98 promoter late in infection.
By comparison, the UL98 early promoter characteristics in the regulation of early 
gene expression is markedly similar to other early promoters. Activation occurs via 
multiple cis-acting elements and both viral and cellular trans-acting proteins; namely 
IE72, IE8 6 , CREB/ATF, AP-l. CREB/ATF factors in particular seem to play a crucial 
role in IE and early viral gene expression including promoters of the MIE region, UL54, 
UL112-113, USl 1, and UL98. These studies support CREB/ATF family members as
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
135
participants in the regulation of viral genes which are germane to the replication of 
HCMV.
Early gene expression is considered the point of commitment for viral DNA 
replication. While a number of essential early genes have been characterized thus far, 
and clearly contribute to the propagation of HCMV, the UL98 gene is nonessential for 
HCMV replication in tissue culture. The UL98 gene product has been shown to be 
important in viral egress and therefore aids in the packaging and release of virus (47, 167, 
169). It is, therefore, of interest to us to determine if mechanisms which apply to 
activation of promoters for essential genes reflect general mechanisms of early gene 
activation or if they are specific for a particular subclass. The UL98 gene is defined as an 
E3 early subclass gene that is activated early and mRNA increases steadily though late 
times. The UL98 gene product then functions in maturation. It is necessary to address 
how the 5’ regulatory sequences functionally compares and contrasts in relation to 
promoters for genes of the El, E2, and E3 subclasses. Clearly, early viral genes utilize 
some of the same cellular factors for regulation but also require diverse regulatory 
mechanisms for their regulated expression from the initiation of transcription to protein 
stability. These studies may identify key factors involved in activating these genes which 
may be exploited as targets for the development of effective anti-HCMV therapies.
While transient assays are useful for identifying sequences important for gene 
expression, this artificial system is limited in displaying the multiple regulatory 
influences put forth by HCMV during normal viral infection. Additional IE proteins 
(IRS1/ TRS1, UL36-38) as well as early proteins (UL112-113) of HCMV influence the 
promoter activation of several early genes. Experiments in which the reporter plasmid
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
136
containing the promoter of interest is transfected into cells followed by infection with 
virus (superinfection) clearly show that additional regulatory proteins are necessary for 
full promoter activation. In this way, viral transactivators not present in a cotransfection 
with IE expressing plasmids, can act upon the promoter. It has been shown in previous 
studies that template-specific differences exist between plasmid DNA and viral DNA (8 8 , 
180, 209). Late induction of the 1.2 kb RNA promoter observed in infected cells does 
not occur when promoter is in a plasmid in transient transfection assays unless origin of 
replication, orilyt, is present (209). Although one can study gene expression in infected 
cells, a true reflection of the regulatory events of early gene expression is not evident. In 
short, the assays used to this point still lack a biologically relevant environment.
Several studies have been undertaken to assess the role of elements in regulating 
HCMV promoters in the context of the viral genome. Rodems et. al. sought to determine 
the various response elements within the UL112-113 promoter at different times 
postinfection (152). In transient assays, the ATF/CREB site is essential to promoter 
activity and is shown by a mutant ATF/CREB abolishing early RNA synthesis. The 
transcription at late times is similar to wildtype. A weak IE8 6  binding site is 
nonessential, but enhances the transcription of UL112-113 (152). A mutant IE8 6  is 
decreased in early expression and is abolished late. Upon the generation of ATF/CREB 
and IE8 6  mutants inserted into the viral genome, ATF/CREB functions only at early 
times and IE8 6  is required for the activation of late transcription (152). Studies by Kerry 
et. al. show inverted repeat 1 (IR1) dependent activation of UL54 promoter in transient 
assays (90). IR1 mutated in the context of the viral genome reflects IR1 independent 
activation and instead relies upon the transcription factor binding site ATF for activation
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at late times (8 8 , 89). These studies reveal a more precise view of the regulatory events 
that take place in HCMV early promoter activation and is observed when the promoter 
sequences are inserted into and tested in the viral genome.
To more precisely evaluate the multiple regulatory influences of the virus on 
UL98 promoter activation, the wildtype and relevant mutant promoters will be studied in 
the context of the HCMV genome in the established recombination system utilized by 
Rodems and Kerry. In the following studies, the promoter-CAT constructs previously 
generated for mutagenesis studies will be inserted into the viral genome in place of the 13- 
glucuronidase gene located in a nonessential region of the RV134 strain of the HCMV 
genome. More specifically, mutations that may affect response elements in transient 
analysis will be cloned into the recombination vector pRC to target insertion into the 
US9-10 intergenic region of the HCMV genome. The constructs are then transfected into 
HFF1 cells in the presence of RV134 DNA. RV134, which expresses the marker (3- 
glucuronidase, will lose the marker gene after recombination and the phenotype of the 
progeny virus will change from blue to white plaques. The viruses positive for a white 
plaque phenotype will then be isolated by plaque purification methods and characterized 
for the appropriate insertion of the promoter-CAT construct and proper growth kinetics 
compared to wildtype RV134. The viruses will then be tested for levels of CAT RNA by 
northern blot analysis and protein by western blot analysis during infection.
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CHAPTER VI 
CONCLUSIONS
The HCMV UL98 early promoter of the alkaline exonuclease gene was 
characterized to better understand the events that occur during the early phase of virus 
replication. The specific sequences involved in conferring UL98 promoter activation by 
immediate early (IE) proteins as well as the identification of viral and cellular proteins in 
the regulation of early gene expression was investigated. To determine the sequences 
important for the activation of the UL98 promoter, the UL98 regulatory sequences were 
tested in transient expression assays in a reporter-C AT construct. The promoter was 
activated synergistically by IE proteins IE72 and IE8 6 . Deletion analysis revealed that a 
13 bp sequence from -64 to -51 was essential for activation by viral regulatory proteins. 
The specificity of sequences necessary for UL98 promoter activation was also 
determined. Specific cellular response elements within and flanking the 13 bp region 
were mutated by site directed mutagenesis. Two elements, the cyclic AMP response 
element (CRE) and the gamma interferon response element (yIRE), when mutated in the 
context of the UL98 promoter, negatively impacted promoter function in response to 
HCMV infection throughout the course of infection. Cellular factors were found to bind 
UL98 promoter sequences. As a result of binding assays utilizing specific cellular 
response elements in the presence of HCMV infected cell nuclear extracts, the cellular 
transcription factor CREB was found to be a component of the proteins that bind the 
UL98 promoter region. Specific binding was observed for interferon regulatory elements 
as well, although the protein(s) involved were not identified in these studies. In
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summary, the overall conclusion in the characterization of the regulatory sequences of the 
UL98 early gene was that regulation of early gene expression requires the cooperation of 
the specific promoter sequences CRE and ylRE. The HCMV viral proteins IE72 and 
1E86 in addition to the cellular protein CREB facilitate this activation through 
protein/DNA binding and likely protein-protein interactions. The assessment of the 
UL98 promoter sequences is consistent with regulation of other HCMV early promoters. 
Future studies in the context of the viral genome may provide a more accurate view of the 
multiple regulatory influences in UL98 gene expression.
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APPENDIX L
LIST AND DESCRIPTION OF PLASMID DNAS OBTAINED FROM OTHER 
SOURCES OR PREVIOUSLY CONSTRUCTED
pSVOCATd- contains the chloramphenicol acetyltransferase gene and is derived from 
pGEM vector.
pSVOd- vector used to construct IE gene region plasmid.
pSVCC3- plasmid containing the IE1 gene region plasmid.
pACC- same as pSVCC3 except contains the IE2 gene region plasmid.
pIE72kD- IE1 cDNA under control of MIEP, codes for the 72 kD protein.
pIE86kD- same pIE72kD except IE2 cDNA codes for the 86 kD protein. 
pSVH- IE 1/IE2 gene region plasmid.
pCBX8.1- 8.1 kb BamHl to Xbal fragment of Xbal-C containing the pp28 gene
region.
ppolCAT- contains the HCMV polymerase promoter (-460 to +20) cloned into 
pSVOCATd
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APPENDIX IL
LIST OF PLASMIDS CONSTRUCTED DURING THIS STUDY.
pUL98CAT- UL98 promoter fragment (-309 to +112) of 421 base pairs (bp) cloned into 
reporter CAT construct pSVOCATd. 
pdH309CAT- same plasmid as pUL98CAT except the downstream HindiII site at +112 
has been inactivated.
Deletion Mutants: p*CAT- where * indicates site of specific deletion or mutation. 
P-194CAT- pdH309CAT deleted from Hindlll (-309) to Nar\ (-194).
p-136CAT- pdH309CAT deleted from Hindlll (-309) to Sunl (-136).
p-85CAT- pdH309CAT deleted from Hindlll (-309) to Hindlll inserted at -85.
p-64CAT- pdH309CAT deleted from Hindlll (-309) to Hindlll inserted at -64.
p-51 CAT- pdH309C AT deleted from Hindlll (-309) to Mscl (-51).
P-34CAT- pdH309CAT deleted from Hindlll (-309) to Hindlll inserted at -34.
P-28CAT- pdH309CAT deleted from Hindlll (-309) to Hindlll inserted at -28.
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Substitution Mutants (context specific!:
Wild-tvne promoter: p*CAT- where * indicates site of mutation. 
pCm5CAT- 5' portion of CRE site replaced with an EcoRl site (GAATTC). 
pTmCAT- TCF replaced with an EcoRl site (GAATTC). 
pCmTmCAT- both CRE and TCF replaced with an EcoRl site (GAATTC). 
pSmCAT- SIE replaced with an EcoRl site (GAATTC). 
plmCAT- ylRE replaced with an EcoRl site (GAATTC). 
pSmlmCAT- both SIE and ylRE replaced with an EcoRl site (GAATTC).
-85 mutants: p-85*CAT- where * indicates site of mutation. 
p-85CmCAT-CRE site replaced with an EcoRl site. 
p-85TmCAT- TCF site replaced with an EcoRl site. 
p-85CmTmCAT- both CRE and TCF sites replaced with an EcoRl site. 
p-85SmC AT- SIE site replaced with an EcoRl site. 
p-85ImCAT- ylRE site replaced with an EcoRl site. 
p-85SmImCAT- both SIE and ylRE sites replaced with an EcoRl site.
-64 mutants: p-64*CAT- where * indicates the site of mutation. 
p-64TmCAT- TCF site replaced with an EcoRl site. 
p-64SmCAT- SIE site replaced with an EcoRl site. 
p-64ImC AT- ylRE she replaced with an EcoRl site. 
p-64SmImCAT- both SIE and ylRE sites replaced with an EcoRl site.
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-51 mutants: p-51*CAT-where * indicates the site of mutation. 
p-51SmCAT- SIE site replaced with an EcoRl site. 
p-5 llmCAT- ylRE site replaced with an EcoRl site.
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APPENDIX m .
LIST OF PRIMERS USED FOR THE GENERATION OF DELETION AND 
SUBSTITUTION MUTATIONS BY OVERLAPPING PCR MUTAGENESIS
General primers used in ail overlapping PCR mutagenesis reactions and d primers
5’aa- 5’GCATCTGTGCGGTATTTCACACCG3 ’*
5’aaa- 5’CCACCTCTGACTTGAGCGTCGATT3’*
3’dd- 3GGATATTGGTCTGGCAAGTCGACC5’
(*Note: 5' primers contain different G/C content necessary for match with G/C content of 
internal primer.)
Primers generated for deletions (c and b primers)
HSI(s)(/f/ndm between SIE and JREX-34)-
5 ’ GGCC ACGAGCG AAAGCTTGT ATTT AT AT AACGCCTTTCGGCGC3 ’ 
HSI(as)(-34)-
3 CCGGTGCTCGCTTTCGAACATAAATATATTGCGGAAAGCCGCG5 ’ 
HMT(s)(H//i£/in at the Minimal TATA)(-28)- 
5 ’GCGACGGGCTGAAGCTTTAT AACGCCTTTCG3 ’
HMT(as)(-28)- 3 CGCTGCCCGACTTCGAAATATTGCGGAAAGC5’
HIC(s)(A[/nc/III between Inverted repeat and CRE)(-85)- 
5 TCGCAGACCATGAAGCTTGAATACGTC AGAAAGAACGTG3 ’
HIC(as)(-85)- 3 CAGCGTCTGGTACTTCGAACTTATGCAGTCTTTCTTGCA5’ 
H CT(sX ^/^m  between CRE and !CF)(-64)-
5’GAAT ACGTC AGAAAGAAGCTTGAGCGTCTGTTGGCC ACGA3 ’
HCT(as)(-64)- 3 CTTATGCAGTCTTTCTTCGAACTCTCATACAACCGGTGCT5’
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Primers generated for substitution mutations
CRE-1 m- 5’CCATGCTGCACGAAGAATTCAGAAAGAACGTGGAG3 ’
CRE-2m- 3 ’ GGTACGACGTGCTTCTTAAGTCTTTCTTGC ACCTC5 ’
TCF-lm- 5 GAAAGAACGTGGAGCGGAATTCGGCCACGA3’
TCF-2m- 3 CTTTCTTGCACCTCGCCTTAAGCCGGTGC5’
CmTrill­
s ’GCTGC ACGAAGAATTC AG AAAGAACGTGG AGCGG AATTCGGC C AC3 ’ 
CmTm(as)-
3’GACGTGCTTCTTAAGTCTTTCTTGCACCTCGCCTTAAGCCGGTGC5’
SIEni2(s)-
5CCACGAGCGAATTCCTGTATTTATATAACGCCTTTCGGCGCACCACCAGC3’
SIEm2(as)-
3 ’GGTGCTCGCTT AAGGAC AT AAAT ATATTGCGGAAGCCGCGTGGTGGTCG5’ 
YlREm(s)- 5’CC ACGAGCGACGGGGAATTCTT AT AT AACGCCTTTCG3 ’ 
YlREm(as)- 3 ’GGTGCTCGCTGCCCCTT AAGAAT AT ATTGCGGAAAGC5 ’ 
Smlm(s)- 5 ’GGCC ACGAGCGAATTCGAATTCTTAT AT AA3 ’
Smlm(as)- 3’CCGGTGCTCGCTT AAGCTT AAGAAT AT ATT 5 ’
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